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Success has many fathers, failure is an orphan. 

CHAPTER I 
Short summary of the literature and discussion of 
the results of the investigations 
The evolution and natural course of human coronary artery disease and risk factor 
mitigation programs can be studied by comparing sequential coronary angiograms 
of the same patient at different moments in time. 1 Although tens of thousands of 
angiograms are performed each year to elucidate the possible anatomical substrate 
of clinical manifestations, a very limited number is carried out to assess the effects 
of an intervention with the aim to decelerate the natural progression of coronary 
artery disease. As having a distorted lipid metabolism is one of the main risk 
factors which tend, if uncorrected, to accelerate the natural course of coronary 
atherosclerosis, several studies have been published that focus on the effect of lipid 
lowering on coronary atherosclerosis. A clear relationship between lipoprotein 
concentrations and severity of atherosclerosis has been shown to exist,23 and the 
results of nine intervention studies with regard to coronary atherosclerosis, carried 
out between 1975 and 1985 are summarizes in Table I. A brief description of these 
follows. 
Cohn et al.4 used clofibrate in 40 severely atherosclerotic diseased patients. No 
diet was prescribed and the angiograms were assessed by visual interpretation. 
Sequential angiography with an interval of one year, showed regression to occur 
(data not shown). Blankenhorn et al. 5 studied femoral arteries. For intervention 
they used a lipid lowering diet and (mainly) clofibrate. With a computerized 
measuring technique the authors noted that after one year, regression of athero-
sclerosis had occurred in 14 of25 patients. Rafflenbeul eta!. 6 used a Vernier caliper 
to measure coronary diameters on the two sequential angiograms of patients with 
unstable angina carried out with an interval of one year. Patients were given an 
'optimal' medical treatment. Five of the 25 patients studied showed signs of 
coronary atherosclerotic regression. No specific lipid lowering therapy or diet was 
administered. Kuo et al. 7 used diet and colestipol in the treatment of hyperlipide-
mic patients. The average interval for sequential coronary angiography was three 
years. In twenty-one of the 25 patients studied atherosclerotic lesions stabilized. 
Nash et al. 8 had similar results when he prescribed colestipol to 42 patients for 2 
years. Duffield et a1.,9 studying femoral arteries, used diet, cholestyrarnine, nicoti-
nic acid and clofibrate for intervention. With repeat angiograms performed after 18 
months, 71 out of the 300 segments studied showed signs of regression of atheros-
clerosis. Nikkilii et a!, 10 used diet, clofibrate and nicotinic acid as a lipid lowering 
therapy. When the repeat angiogram was performed after three years the therapy 
resulted in a slower rate of progression of coronary artery disease. Brensike et al, 11 
who used diet and cholestyramine found 5 years later definite signs of regression of 
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coronary atherosclerosis in the repeat angiograms in 18 of the 116 patients studied. 
Arntzenius et a!. ,'2 with a computerized measuring technique to 'read' coronary 
angiograms found definite regression to occur in 7 of the 39 patients who participa-
ted in the study, while stabilization of the lesions was seen in 11 patients. 
Sequential angiography was performed after two years of study and (lipid lowe-
ring) intervention consisted solely of diet. 
All of the above mentioned studies with the exception of those of Cohn and 
Rafflenbeul showed a definite correlation between the anatomical changes obser-
ved and serum cholesterol levels. Since the natural history of coronary artery 
disease when no intervention is undertaken, seems to be one of an unequivocal 
progression,'·14 any possibility to decelerate lesion growth should be viewed with 
great interest. Even a slight deceleration if extrapolated on a lifetime period, could 
mean an amelioration of the quality of life. 15 Further research should be directed 
towards a thorough analysis of the relation between angiographic findings and 
pathological substrate of coronary stenosis.1" 18 However, we should keep in mind 
that the physiological state of the patient (during coronary angiography) may 
substantially influence the results. Dynamic changes in luminal diameter due to 
varying vasomotor tone, platelet aggregation, thrombolysis or the state of the local 
atherosclerotic disease itself may alter the angiographic apperance of the dis-
ease.19·20 With the development of computerized quantitive measuring methods of 
arterial luminal width on coronary angiograms a more sophisticated and reliable 
tool has come to hand to limit bias and variations in angiograms interpretations. 21.22 
There is growing evidence that the process of atherosclerosis e.g. lesion growth 
of the plaques can be halted or perhaps even be reversed. 23•24 Nine studies that 
made use of interventions, and that were probably by no means optimal, tended to 
show that regression of atherosclerosis is feasible. Larger controlled studies are 
required to show by which type of intervention (diet and/or drugs) regression of 
atherosclerosis can be achieved most efficaciously. Before we are able to study the 
process of progression and regression of atherosclerosis, we should review the 
origins of the disease before we are capable to make decisions that may influence 
the natural course. 
Large epidemiological studies have shown that lipid disorders are strongly correlat-
ed to morbidity and mortality of cardiovascular diseases. 16•17 Cholesterol, the most 
important lipid, is mainly transported in the low-density-lipoprotein (LDL) frac-
tion of the lipoproteins. Other lipid fractions are triglycerides, which are mainly 
carried by chylomicrons and very-low-density-lipoprotein (VLDL) and phospholi-
pids which are principally found in the high-density-lipoproteins (HDL). The 
distinction between these before mentioned lipoprotein fractions, is made on the 
basis of variations in size, density, lipid composition and apolipoprotein content. 
LDL(-cholesterol) is positively correlated to coronary artery disease (CAD), 
while HDL-cholesterol (HDL-C) has an inverse correlation to this process. There-
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TABLE I 
Arteriographic assessment of interventions studies on atherosclerosic lesion growth 
Author Yea< Num- Artery Dwca- Drug used Diet Con- Measure- Correlation Definite 
pu- ber of studied tion trolled ments tech- of lesion regression 
blished patients study Diques* change to SC· 
in- rum choleste· 
volved rol value 
Cohn et al 1975 40 coronary 1 yr clofibrate + visual (4) 
Blanken· 1978 25 femoral 1 yr clofibrate + - visual+ + 14/25 pts. 
hom et al (+ neo- computer 
mycin) 
Rafflen- 1979 25 coronary 1 yr optimal - vernier 5/25 pts. 
beul et al med. caliper 
treatm. 
Kuo et al 1979 25 coronary 3 yrs colestipol + visual (3) + 
Nash et al 1982 42 coronary 2 yrs colestipol visual (2) + 
Duffield 1983 24 femoral 1.5 yrs cholestyr., + + visual+ + 71/300 
eta! nicot. acid computer segm. 
clofibrate 
Nikkila 1984 30 coronary 3 yrs clofibrate + - visual (2) + 
eta! nicot. acid 
Brensike 1984 116 coronary 5 yrs cholestyr. + + visual (3) + 181113 pts. 
eta! 
Amtze- 1985 39 coronary 2 yrs + - visual (2) + 7/39 pts. 
nius et al +com-
puter 
* number of independent observers 
segm. == segments 
pts. = patients 
fore, they" are respectively considered as 'atherogenic' cholesterol and 'anti-
atherogenic' cholesterol. 18·19 Other fractions like chylomicrons and VLDL are not 
conclusively correlated to atherosclerosis development.20•21 As a high LDL-Ievel is 
accelerating CAD development and a high HDL-Ievel is retarding this growth, an 
investigation was undertaken to assess the risk factor profile in CAD in male 
survivors one year after they had suffered a first acute myocardial infarction 
(AMI). The results of this investigation indicate that, contrary to the patients with 
age in the general population, total-cholesterol (TC) and triglycerides (TG) were 
significantly higher in the younger patients than in the older ones while HDL was 
significantly lower as compared to the older age groups (Chapter II). Although 
these findings are in accordance with the risk factor principle they are nevertheless 
disappointing. Apparently during the one year period after the AMI, lipid disor-
ders were not sufficiently assessed and adequately treated. Although the most 
firmly established risk factor for CAD development remains a disordered lipid 
metabolism, cigarette smoking and systemic hypertension appear also to be of 
great importance. The exact mechanism by which smoking is harmful to the heart is 
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unknown.22 Nevertheless, accelerated coronary atherosclerosis has been reported 
in smokers. 23•24 A specific pattern of coronary atherosclerosis as assessed by 
coronary arteriography has been established under these circumstances. 25 An 
interesting aspect concerning smoking and CAD is the fact that a survivor of an 
AMI who gives up smoking has been shown to improve the life expectancy. Two 
distinct mechanisms of the harmful effects of smoking can be described. One, that 
induces cardiac arrhythmias and one, that acts slowly and is compatible with an 
accelerated rate of the atherosclerotic process. In the before ·mentioned risk factor 
analysis study in which male survivors of an AMI were evaluated, a significant 
difference was found between the three age groups assessed (Chapter II). The 
youngest group of patients, forty years or younger, all smoked before they suffered 
an AMI. Other risk factors considered were hyperlipoproteinemia and hyperten-
sion. Much has been said about hypertension and its treatment in cardiovascular 
diseases. The fact that hypertension is strongly and positively correlated to 
cerebrovascular diseases but not whith CAD, is of particular interest. 26·27 Other 
points worth noting are the metabolic side effects of antihypertensive drugs. 
Therefore, the gain in risk factor lowering may be lost due (to facilitation) of the 
induction of atherogenic metabolic disorders. 28 It is noteworty that the etiology of 
hypertension is unknown, that treatment is almost always possible and that other 
factors like lipid disorders must play a role, before hypertension can express itself 
in CAD. 2956 Nevertheless, in view of the assessment of the high frequency of lipid 
disorders in a group male survivors of an AMI, an evaluation of the incidence of 
risk factors is of great importance given the life expectancy of these young patients. 
In this evaluation study, hypertension was more prevalent in the younger patients 
than in the older age groups (Chapter II). This finding should be viewed while 
keeping in mind the fact that due to an AMI, left ventricular muscular mass is lost 
and as a result, the individual is less capable to develop systemic hypertension. 
How hypertension in CAD may accelerate atherosclerosis when hyperlipidemia is 
present, remains to be investigated, although several proposals have been made. 30 
Recently several studies have been published, stressing the importance of 
treatment of (even) mild hypertension.31"33 From these studies one may derive that 
antihypertensive treatment does not affect mortality or morbidity of CAD. Antihy-
pertensive treatment affects the incidence of cerebrovascular diseases, although 
even here the cost-benefit ratio is high. 
Coronary prone behavior or type 'A' behavior has been described as an 
important and independent risk factor for CAD. 34 This behavioral pattern has been 
significantly more prevalent in young male survivors of an AMI than in older age 
groups (Chapter II). Encouraging results have recently been published of attemps 
to mitigate this kind of behavior. 35 
Although many more coronary risk factors may contribute to CAD, with regard 
to their relatively lower grade of importance, these factors have not been 
investigated by us. 36 
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As serum lipoproteins remain the most important determinants of coronary 
atherosclerosis growth, modulators of lipoprotein metabolism are thought to play a 
prominent role. The postheparin lipoprotein lipase activities are lipoprotein modu-
lators and can be divided into lipoprotein lipase (LPL) and liver lipase activity or 
hepatic lipase (HL). Both are located in the endothelial cells lining blood vessels. 
LPL may regulate the catabolism of triglyceride rich lipoproteins, chylomicrons 
and VLDL,and may therefore modulate to a certain extent part of LDL metabo-
lism.37 Recently published reviews indicate the importance of LPL as HDL 
modulator.38 The exact function of the other postheparin lipoprotein lipase, HL is 
less clear. 39 Data from several studies have indicated that HL may be associated 
with the conversion of intermediate-density-lipoprotein (IDL) to LDL.40 Another 
function may be clearing of cholesterol into bile through an intervention in the 
HDL metabolism.39 
In a controlled study that compared male patients with diffuse severe athero-
sclerosis on the coronary angiogram with angiographically assessed coronary 
atherosclerosis-free individuals, LPL and HL were measured. In the atherosclero-
tic group HL was significantly lower than in the other group and LPL had identical 
(normal) values in both groups (Chapter HI). 
In the Lei den Intervention Trial (Chapter IV), in which sequential coronary 
angiography was performed to assess progression of atherosclerosis during vegeta-
rian dietary intervention, HL and LPL were measured. By multivariate analysis 
HL was shown to be the variable correlated most strongly with regression of 
atherosclerosis (Chapter V and VI). Although aspects of Chapter V contain some 
data used in Chapter VI, only the former paper contains the crucial description of 
the methodology used to assess quantitative coronary atherosclerosis measure-
ments. Furthermore, ouly Chapter V contains the data and the discussion concer-
ning different response patterns to dietary interventions on the lipoprotein lipases 
values, and all atherosclerosis linked hormones (Chapter V, Table VI). 
Those patients who showed initially a high TC/HDL-C ratio and who showed 
benefit from dietary intervention (with significant lowering ofTC/HDL-C ratio) by 
showing a regression or no progression of coronary atherosclerosis had normal HL 
values, while the patients who showed further progression of the atherosclerotic 
process at least ultimately, had low HL values. The LPL values were not different 
in the groups with progression and regression (or no progression) of coronary 
atherosclerosis, respectively. 
Another aspect which may further elucidate the mechanism of regression of 
atherosclerosis is the fact that in the patients with regression or no progression of 
atherosclerosis triiodothyronine (T 3) was significantly higher than in the group with 
progression of atherosclerosis, independent from the lipid fractions (HDL, LDL, 
TG, TC, VLDL) and the lipoprotein lipases, HL and LPL. The T4 fraction is 
considered the thyroid hormone 'pool' from which in the peripheral tissues, maiuly 
the liver, the metabolically active T3 is formed by conversion.41 It is well known that 
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betablocking agents inhibit this conversion. No significant difference could be 
found in the number of patients treated with these agents in the groups with 
progression and regression or no progression of atherosclerosis, respectively 
(Chapter VI). It is well known that hypothyroidism induces an elevation of LDL 
and that thyroid hormone substitution normalizes this lipoprotein fraction 42 This 
effect was clinically tested in the Coronary Drug Project by the administration of 
thyroxine to euthyroid patients suffering from coronary atherosclerosis, but this 
study had to be stopped prematurely due to the development of cardiac arrhyth-
mias"' No assessment of the development of coronary atherosclerosis and its 
complications was performed. In the Leiden Intervention Trial no significant 
correlation between thyroid hormone levels and postheparin lipoprotein lipases 
could be demonstrated (Chapter VI). 
Another aspect of the epidemiology of CAD is the striking higher in incidence in 
men when compared to pre-menopausal women. Post-menopausal women have 
the same incidence of CAD as men. 44 This observation together with the fact that 
there is evidence that a high estradiol level in men may promote AMI,45 has led to 
investigate sex hormones in coronary atherosclerosis. In an earlier investigation we 
could not find a relationship between plasma testosterone and the HDL-choleste-
rol fraction.46 In another study (Chapter HI) we found a significantly higher 
estradioVtestosterone ratio in normolipemic men with severe diffuse coronary 
atherosclerosis than in men angiographically free from coronary atherosclerosis. It 
should be stressed that the patients in this study represented two extremes of the 
atherosclerosis spectrum, while in the Leiden Intervention Trial (Chapter IV), 
where we did not observe such a difference between the progression and the 
regression group, there was a relatively small difference in the severity of the 
atherosclerotic process. Nevertheless, we feel that in men sex hormones, by 
modulating the lipid fractions, may directly or indirectly play a role in the 
progression of atherosclerosis. 47 
Glucagon, a biologic antagonist of insulin, is a hormone that to a large extent 
regulates blood sugar levels in response to sudden changes in the provision of 
energy.48 Glucagon, therefore, may be a risk factor in the process of coronary 
atherosclerosis. Insulin is supposed to be atherogenic in adipose people. 49 There-
fore, we assessed both glucagon and insulin levels in the above mentioned two 
groups of men. The group with coronary atherosclerosis did show a significantly 
higher glucagon level than the coronary angiographically atheroslerosis-free indivi-
duals. Insulin was not different between the groups (Chapter III). Other studies 
have indicated the importance of insulin for the HDL-cholesterol metabolism. 50 In 
this respect we did not find a difference between the groups that showed progres-
sion and regression of CAD, respectively. 
Cortisol has been found to be related to type 'A' behavior,51 that constitutes an 
independent risk factor for CAD and early atherosclerosis in generaL52 In our 
study comparing men with advanced atherosclerosis with men who were free from 
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coronary atherosclerosis, no significant difference in plasma cortisol levels were 
found between the two groups. Likewise, no difference in plasma cortisol was 
observed between the progression and regression group of patients in the Leiden 
Intervention Trial (Chapter IV). This intervention study was undertaken with the 
aim of assessing the influence of a vegetarian lipid lowering diet enriched in 
polyunsaturated fatty acids. 
As a large groups of patients for a long period of time are required to evaluate 
the effects of the intervention on complications of coronary atherosclerosis, 
sequential coronary arteriographies were chosen as means of assessing the effect on 
atherosclerosis lesion growth. With the development of quantitative computerized 
analysis methods, a reliable method became available.'-5,.55 The natural history of 
the disease has been described as almost unequivocally progressive,56 but the 
methods used in most intervention programs are too unreliable to make statements 
with regard to the influence of an intervention. 57 Review articles have established 
that the evaluation of coronary atherosclerotic regression is feasible in all species 
including humans. SS-60 In the analysis of a coronary angiogram change in the 
vasomotor tone has been included61 After the development of a reliable quantita-
tive computerized method, the Cardiovascular Angiographic Analysis System 
(CAAS), a scoring system had to be developed. This coronary scoring system was 
based on the relative importance of blood flow in the different coronary seg-
ments."2 (Chapter V). 
Although complications of the natural progressive nature of coronary atheroscle-
rosis may be an acute expression of the disease, 63 the underlying slowly progressive 
process should be halted or at least the annual increment diminished. 64 As strong 
relationships exist between diets and lipids on one hand and between lipids and 
progression of CAD on the other hand, 65 a vegetarian diet enriched in poly-
unsaturated fatty acids and low in cholesterol with a twice a week allowance of lean 
fish was chosen6 6-71 
The principal outcome of The Leiden Intervention Trial, that regression of 
coronary atheroslcerosis can be induced by (lipid lowering) dietary means only, is 
of great importance. The clinical significance of these results show that regression 
of coronary atherosclerosis in men is significantly correlated with survival and 
disappearance of the orginal anginal complaints (Chapter VII). 
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CHAPTER II 
Cardiovascular risk factors in men ( 49 years or 
younger), survival one year after a first myocardial 
infarction. 
Jacques D. Barth M.D., Geert T. Meester M.D., Jacobus Lubsen Ph.D. 
orginal publication in dutch entitled: Cardiovasculaire risicofactoren bij mannen (49 jaar of jonger) een 
jaar na her eerste myocardinfarct (Ned Tv Geneesk 1985; 129: 1378-1381). Appendix paper I. 
Summary 
Risk factors (hypertension, total serum cholesterol, HDL-cholesterol, triglycerides, 
a positive family history for cardiovascular diseases, smoking and Type 'A' 
coronary prone behavior were investigated in men who had suffered a first 
myocardial infarction. 
Three age groups were compared (40 years of age or under, between 4~ and 49 
years and 50 years and above). Results show a higher incidence of risk factors in 
the younger age groups both before and after myocardial infarction. Lipid disor-
ders were especially implicated. Our findings are discussed with special focus on 
the possibility to mitigate these risk factors. 
Introduction 
Myocardial infarction is a complication of a heart disease in which risk factors are 
considered to contribute to the progression of the underlying coronary atheroscle-
rotic disease. 
Major risk factors are the male sex, hypertension, hyperlipoproteinemia, smo-
king, glucose intolerance, a positive family history of cardiovascular diseases and a 
certain type of psychological behavior. 1"3 Results of the modification of these risk 
factors in large scale studies are inconclusive.45 A subgroup, however, with a high 
incidence of risk factors may be prone to benefit from intervention. Male patients 
under the age of 50, who had sustained a myocardial infarction can be considered 
to be such a group, apparently at high risk. We studied the risk factor profile in a 
series of these patients one year after they had suffered a first myocardial 
infarction. 
Patients and methods 
All male patients over a period of one year, who were 49 years of age or younger at 
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the time of their myocardial infarction and were treated in the Coronary Care Unit 
of the Thorax center Rotterdam, The Netherlands, were asked to participate in the 
study. In this period (from June 1981-June 1982), 252 male patients and 70 female 
patients with a respective average age of 58.2 years and 61.9 years were admitted 
for a first myocardial infarction out of 1121 admissions. Thirty-six men and 16 
women had died in the hospital phase leaving 216 men and 54 women eligible for 
the follow-up study. Of the total male population (n=216), 52 patients were 49 
years or younger at the time of the myocardial infarction. Five patients (9 .6%) had 
died during the one year interval period. Furthermore during this period two 
patients has suffered a recurrent myocardial infarction, two patients had undergone 
a coronary bypass grafting and one patient had emigrated to a foreign country. A 
total of 42 patients under the age of 50 years were available for our investigations. 
Thirty patients participated in the study at the out-patient clinic of the Thoraxcen-
ter in Rotterdam. The remaining twelve patients, who did not want to participate 
were alive and well at the time of the survey period. Of the thirty participants 
under the age of 50 years, twelve were 40 years or younger and eighteen were 
between 40 and 50 years of age. As a control group, a random sample of20 patients 
out of the remaining 200 patients of 50 years or older was taken. The same 
procedure was performed to check the risk factors in the respective three age 
groups. 
The patients were asked to report back to the out-patient clinic one year after the 
myocardial infarction. At this follow-up visit a physical examination was perfor-
med, a questionnaire was filled out by the patient, and a fasting bloodsample was 
collected for measurements of several lipid fractions (total-cholesterol," HDL-
cholestero1,7·8 triglycerides!) and glucose. None of these patients were known to 
have diabetes mellitus or a familiar hyperlipoproteinemia before they suffered a 
myocardial infarction. 
The questionnaire contained the following questions: 
1. Are you now on any form of diet? 
2. Are you using any tobacco now and were you using any before your myocardial 
infarction? If so, in what form and how much a day? 
3. Are you known to have been suffering from hypertension? 
4. Does coronary heart disease run in your family? If so, please give details. 
5. Do you feel you were experiencing excessive emotional stress before your 
myocardial infarction, like living under time pressure limits, restlessness or 
unexplained feeling of depression? 
One risk factor was considered to be present if the patient showed one of the 
following: 
1. a serum total-cholesterol value of 290 mg/dl or above. 
2. a serum high-density-lipoprotein (HDL)-cholesterol value of 30 mg/dl or below. 
3. smoking more than 5 cigarettes a day. 
4. a blood pressure in excess of 150 mmHg systolic and/or 90 mmHg diastolic. 
24 
5. a positive family history for cardiovascular diseases, if a first degree relative had 
a myocardial infarction, a cerebrovascular accident, or died suddenly under tbe 
age of 60 years. 
6. signs and symptoms of coronary prone behavior (type 'A'-behavior). 
If present, one point per risk factor was added to tbe risk factor sum of the 
patient. 
All patients studied were of Dutch descent. 
Results 
Risk Factor Profile (Table I): 
No significant difference was found between tbe tbree groups for the risk factors 
hypertension and the number of cigarettes smoked per day. The percentage of 
smokers was significantly different in the sense that in tbe younger age groups more 
patients had smoked. In tbe oldest age group (above 50 years or above) tbe 
percentage of patients who showed coronary prone behavior (20%) or had a 
positive family history for cardiovascular disease (10%) was remarkably low in 
comparison with the younger age groups. 
No patient was on diet at the follow-up visit examination. No glucose intolerance 
was demonstrated by the presence of an elevated fasting blood glucose leveL 
TABLE I 
Risk factor profile in different age groups in men one year after suffering a first acute myocardial 
infarction 
Age (years) !S 40 41-49 ;;?; 50 
(n = 12) (n = 18) (n = 20) 
Bloodpressure of 
;;, 150/90 mmHg 4 4 4 
Positive hypertension history 6 5 5 
Cigarettes smoking 
- Before myocardial infarction 12 15 12 
- After myocardial infarction 3 9 4 
Numbers of cigarettes smoked per day (S.D.) 
- Before myocardial infarction 24 (10) 17 (12) 18 (15) 
- After myocardial infarction 4 ( 6) 5 ( 6) 3 ( 4) 
Positive family history 
for cardiovascular diseases 10 9 2 
Coronary related emotional stress 
perception (type "A· behavior) 8 13 4 
n = number of patients 
Blood lipids (Table II): 
Total serum cholesterol was significantly higher in tbe youngest age group 
(under 41 years) in comparison to the otber groups of patients. HDL-cholesterol 
nor triglycerides were significantly different between tbe tbree age groups. 
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TABLE II 
Lipid values in the different age groups one year after suffering a first acute myocardial infarction 
Age (years) 
Total-Cholesterol 
(mgldl) 
HDL-Cholesterol 
(mgldl) 
Triglycerides 
(mgldl) 
P-vah.ie Student's t test, *""p < 0.01 
all values mean and range 
n = number of patients. 
Patients at risk (Figure 1): 
~40 
(n ~ 12) 
358'"* 
(250-625) 
35 
( 30- 46) 
300 
( 62-698) 
41-49 
(n ~ 18) 
277*'"' 
(227-328) 
39 
( 27- 50) 
229 
(119-548) 
~50 
(n ~ 20) 
274 
(174-302) 
42 
( 34- 53) 
215 
(129-374) 
When all risk factors were considered as a whole, the younger patients showed a 
significantly higher sum than the older age group of patients. 
FIGURE 1 
Total accumulation of risk factors considered 
number of risk 
factors per 
patient 
6 
5 
4 
3 
2 
::-::; 40 41-49 
P < w-s 
Kruskal and 
Wallis18 
~ 50 years 
All values means ± standard deviation of the total number of risk factors present in each group. 
Discussion 
Although the three groups of patients are small and conclusions should be made 
only with great caution, especially considering the fact that in weighting the risk 
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factors we assigned equal contributing weight to the several risk factors in the 
profile. These findings may nevertheless stimulate further discussion regarding the 
treatment of risk factors of special groups with coronary artery disease. Certainly 
one should consider the fact that surviving a myocardial infarction is already a 
selection for the better. 
Serum total-cholesterol tends to be higher in an older population (carrying the 
'atherogenic' LDL-cholesterol). In our study the youngest age group showed a 
serum cholesterol that was higher than the older age groups, implicating a 'special' 
atherogenic aspect in the youngest age group. The HDL-cholesterol, considered to 
be 'anti-artherogenic' as it is inversely correlated to the coronary heart disease, 11 
was not significantly different in the three groups of patients, adding no further risk 
to the different groups. A tendency of a higher value in the older group seems 
worth mentioning. Whether triglycerides are a separate risk factor for coronary 
artery disease, remains to be determined, a trend towards a higher level in the 
younger group appears to be the case in our study. 
As to the other risk factors, of special interest seems to be the fact that all 
patients in the youngest age group smoked cigarettes before suffering an infarction 
and a relatively high percentage (33%) of the patients were supposed to be 
hypertensive before the infarction as measured by a positive history of the patient 
for hypertension. After the myocardial infarction, the younger patients usually quit 
smoking and were less frequent found to be hypertensive as measured at physical 
examination. The high frequency of a positive family history for cardiovascular 
disease and coronary related emotional stress for the younger group is worth noting 
(Table I). 
Several studies in different countries measured risk factors in young patients who 
had symptomatic coronary artery disease. Dolder and Oliver. 12 in their Nine 
Countries Study, found a high frequency of elevated total-cholesterol of 280 mg/dl 
or higher in young male patients after their first myocardial infarction in countries 
with a western style of living. The frequency varied extensively between Israel45% 
and India 1 %; the risk factor hypertension was present in 23% in Australia and 7% 
in Singapore. Smoking varied from 86% in Singapore to 96% in the U.S.A. 
Rosskamm et al. 13 in a similar group of patients as in our study found an elevated 
serum cholesterol (300 mg/dl or higher) in 73% of the patients; 93% smoked 
cigarettes before the myocardial infarction and 30% were hypertensive, Vanhaelke 
et al. 14 found similair results in a Belgium population. Glover et al.15 established in 
a younger population in the U.S.A., that 98% were smoking cigarettes and 21% 
were hypertensive, while a positive history for hyperlipidemia was found in 20%. 
In another U.S.-study by Goldstein et al. 16 the percentage of lipid abnormalities in 
survivors of myocardial infarction was highest in young male patients under 40 
years of age (60%). 
To summarize: The young patient who survived a myocardial infarction smoked 
cigarettes (100%), had a elevated serum total-cholesterol (78%), had a lower 
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HDL-cholesterol (34% ). A positive family history for cardiovascular diseases, 
coronary prone behavior (type 'A') and hypertension were also significantly 
higher. Especially noteworthy, seems to be the finding of a significant inverse 
relation between age and total numbers of risk factors present (Figure 1). In view 
of the sometimes lively debates that followed the publication of the results of 
studies like the MRFIT'·17 one may ask, are not we obliged to treat these young 
male patients at high risk with extra care and vigor? The answer for us is clearly 
affirmative. On the other hand it seems that coronary artery disease in the older 
patient is possible part of the aging process itself and may be in need of an different 
approach than the younger patient who may have a different etiology of the 
pathogenesis of atherosclerosis itself. 
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CHAPTER III 
Post-heparin Lipases, Lipids and Related 
Hormones in Men Undergoing Coronary 
Arteriography to Assess Atherosclerosis 
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The Thoraxcentel and the Department of Internal Medicine Ill University Hospital Rotterdam 
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Summary 
Post-heparin lipase activities were measured in normolipemic men with complaints 
suggestive of symptomatic coronary artery disease. A study group, who showed 
severe diffuse atherosclerotic narrowing of the coronary vessels, as assessed by a 
quantitative computer-assisted analysis method, had a lowered hepatic lipase in 
comparison with a group with normal angiograms. Lipoprotein lipase valuess were 
lower in the study group but well within the normal range and not statistically 
different from the control group. Some atherosclerotic related hormones (cortisol, 
estradiol, testosterone and glucagon) were different in the two groups while others 
(insulin, human growth hormone, prolactin, thyroid hormones) were not. The 
results are discussed iu view of the proposed role of hepatic lipase in the uptake of 
HDL-cholesterol by the liver. 
Introduction 
Serum cholesterol, predominantly transported in the low-density-lipoprotein 
(LDL) fraction, is thought to play a major in the development of atherosclerosis,'·' 
which is reflected in a marked positive correlation between serum (LDL) choleste-
rol levels and the risk of atherosclerosis. High-density-lipoprotein (HDL)-choleste-
rol concentrations are inversely correlated to this risk, and a protective role of this 
fraction against the progression of atherosclerosis has been suggested. 18·11 
The metabolism of the different lipoprotein fractions is closely interrelated.s.u 
Alterations in the metabolism of one of these lipoproteins may reflect changes in 
the overall lipid transport through the plasma and contribute to cholesterol 
deposition leading to atherosclerosis. Therefore, it is of interest to study the 
mechanisms involved in the lipoprotein metabolism in connection with atheroscle-
rosis. 
Two lipases that can be released into the circulation by heparin infusion, 
lipoprotein lipase (LPL) and hepatic lipase (HL), may play iroportant roles in the 
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lipid transport system. Lipoprotein lipase does so by catalysing tbe hydrolysis of 
triglycerides of chylomicrons and very-low-density-lipoproteins (VLDL). This can 
lead to the formation of lipoproteins relatively enriched in cholesterol. 13.14 
Although tbe role of 'liver lipase' or 'hepatic triglyceridase' is not yet established, 
it seems tbat this enzyme plays a key function in lipoprotein metabolism, as 
inhibition of this enzyme activity in situ leads to major changes in plasma 
lipoprotein concentrations. 15-18 · 
Previous studies have shown a decreased activity of post-heparin plasma lipids in 
atherosclerotic patients. 19•20 In these studies, however, lipoprotein lipase and 
hepatic lipase have not been measured separately. We studied both enzyme 
activities in patients witb or without signs of atherosclerosis as assessed by coronary 
arteriography. We also measured serum levels of a number of hormones which are 
known to influence lipid transport and lipoprotein metabolism, and which have 
been suggested to be factors in the development of atherosclerosis. 
Patients 
Male patients under the age of 50 years and of normal weight, in whom coronary 
arteriography has been performed because of complains of severe chest discomfort, 
were selected after reviewing the coronary angiogram. It was required that tbey be 
normolipemic (total-cholesterol < 8.0 mmolll, triglycerides < 2.5 mmolll and 
phospholipids < 3.7 mmolll). Excluded were tbose patients who showed a com-
plete occlusion of a main vessel, in order to avoid acute effects like thrombosis or 
hemorrhage in the vessel wall. All patients witb such known chronic diseases as 
diabetes mellitus and hypertension, or any other disease for which medication had 
to be taken, were excluded. Kidney function as measured by BUN, and creatinine 
and liver functions as measured by bilirubin, SGOT, SGPT, LDH and yGT had to 
be normal. 
Patients in whom the angiogram showed diffuse sclerotic thickening of all tbe 
vessel walls and in at least two of the tbree main coronary arteries (right coronary 
artery, left anterior descending artery and the left circumflex artery) a stenosis of 
>70% in diameter, were considered to have coronary artery disease (CAD). 
Patients were considered to belong to the control group if no visual detectable 
coronary stenosis could be found on the angiogram. Patients with one-vessel 
disease or left main disease, or a history of myocardial infarction, were discarded. 
The two groups were comparable in age, weight, complaints and lipid profiles. 
Absolute diameter measurements of the coronary angiogram were performed by a 
computer-assisted analysis method. 32 
Methods 
Blood was collected after an overnight fast of 14 h and at least 24 h after coronary 
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arteriography. A blood sample was drawn 30 min after the introduction of an 
intravenous catheter. From these blood samples glucagon, insulin, thyroxine, 
triiodothyronine, TTresin uptake, human growth hormone, prolactin, testosterone, 
17~-estradiol and lipids were measured. Immediately thereafter, heparin 50 IU/kg 
body weight (Tromboliquine, Organon, Oss) was administered intravenously. 
Blood was collected in disodium EDTA (2.7 mmol/1) on ice 5 and 40 min after the 
administration of heparin. The blood was centrifuged at 4°C for 30 min at 3000 
r.p.m. and the plasma was stored-20°C. The lipid contents were determined in the 
samples according to the following methods: total-cholesterol, 33 triglycerides. 34 and 
phospholipids.22 HDL-cholesterol and HDL-phospholipids were measured in 
plasma, after precipitation of VLDL and LDL with MnCI2 and heparin.23•24 LPL 
and HL were measured in plasma 5 and 40 min after heparin infusion. 25 Blind 
samples were measured in duplicate for all patients. 
In each series of measurements 2 standard sera with known lipase activity were 
included to control the enzyme essay. Hormone concentrations with known or 
suspected relation to the lipolytic enzymes30•31 were measured in plasma samples 
according to the following methods: glucagon (Novo Industries, Denmark), corti-
sol (I.R.E., Holland), insulin (I.M. C., Holland, MRC 66/304), thyroxine, 28 triiodo-
thyronine,29 T3-resin uptake,28 human growth hormone (I.R.E., Holland), prolac-
tin (I.R.E., Holland), testosterone,26 and 17~-estradiol.27 
The assessments of diameters in the coronary angiograms were performed with 
the assistance of a computerized coronary analysis method32 as to minimise 
problems in interpretation. 
Statistical methods 
Student's t-test was used to compare measurements between the two groups. For 
each variable a P value is given. All results are expressed as means ± standard 
deviation (:X ± SD). As far as applicability of the t-test is concerned, no important 
differences arose when the P-values were compared with those obtained by 
applying Mann-Whitney's test. 
Results 
Lipid analyses 
Serum lipid values for the two groups are presented in Table I. All levels are 
within the normal range and the only significantly different value was that of total-
cholesterol. 
Post-heparin plasma lipases 
LPL reaches a maximal value 40 min. after heparin administration and HL, 
which is more readily released, reaches a maximal value after 5 min. Consequently 
values at 40 and 5 min. are given in Table II. 
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TABLE I 
Serum lipids for the atherosclerotic group (study) and atherosclerotic-free group (control) 
Serum lipids Study 
(n ~ 11) 
Total-cholesterol 6.90 ± 0.77 
Triglycerides 1.48 ± 0.69 
Phospholipids 3.27 ± 0.57 
HDL-cholesterol 1.23 ± 0.21 
HDL-phospholipids 1.65 ± 0.45 
All values are means ± standard deviation in mmol/1 
TABLE II 
Lipolytic lipases (mU/ml) for the two groups studied 
Study 
(n ~ 11) 
LPL (40 min.) 39 ± 10 
HL (5 min.) 125 ± 28 
All values are means ± standard deviation 
1 mU = nmoles free fatty acids released/min. 
TABLE III 
Hormone concentrations for the two groups studied 
Study 
(n ~ 11) 
Testosterone (nmol/1) 17.0 ± 3.2 
17[)-Estradiol (pmol/l) 12S ± 39 
Thyroxine (T,) (nmolll) 105 ± 10.6 
Triiodothyronine (T,) (nmolll) 1.66 ± 0.30 
T3-resin uptake (%) 25.0 ± 2.1 
Cortisol (nmolll) 516 ± 74 
Glucagon (ngll) 60.1 ± 29.6 
Insulin (mUn) 11.8 ± 5.0 
Human growth hormone (ngll) 1.15 ± 0.40 
Prolactin (ngil) 2.6 ± 0.7 
All values are means ± standard deviation 
Hormone concentrations 
Control 
(n ~ 9) 
5.96 ± 0.94 
1.74 ± 0.70 
2.85 ± 0.53 
1.21 ± 0.19 
1.55 ± 0.33 
Control 
(n ~ 9) 
48±11 
176 ± 40 
Control 
(n ~ 9) 
22.7 ± 5.1 
156 ± 43 
87 ± 8.7 
1.50 ± 0.22 
27.3 ± 3.7 
397 ±55 
36.6 ± 15.1 
11.3 ± 4.8 
0.79 ± 0.35 
3.6 ± 0.9 
p 
0.025 
0.386 
0.084 
0.988 
0.282 
p 
0.4810 
0.0070 
p 
0.002 
0.001 
0.048 
0.369 
0.089 
0.046 
0.003 
0.673 
0.604 
0.398 
Hormone values for the two groups are presented in Table III. All values are 
within the normal range. Significantly higher levels of cortisol, glucagon and 
thyroxine were found in the study group. Testosterone and 17~-estradiol concen-
trations were lower in the study group but the estradiol/testosterone ratio was 
increased in these patients (P = 0.036). 
Weight and age 
The mean age of the study group was 45 (35-59) years vs. the control groups 44 
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(32-50) years. The body weight in the study group was 71 ( 63-82) kg vs. 72 ( 62-81) 
kg in the control group. 
Discussion 
Although the two groups were comparable with respect to complaints, age, weight, 
biochemical status and lipid profiles, it cannot be excluded that the two groups 
differed in parameters other than the presence of atherosclerosis. Therefore, the 
interpretation of the P values in this non-randomized study is uncertain. They are 
used here as a basis set for the formulation of hypotheses. It is also questionable to 
what extent the control group had an indication for catheterization. Finally, from 
this type of design it is impossible to determine whether the lipase abnormalities 
observed are induced temporal precursors of atherosclerosis or if they simply 
emerge when atherosclerosis develops. Furthermore, extra care was taken to avoid 
bias, by blinding all measurements and results until the study was terminated. 
The purpose of the study was to assess post-heparin plasma lipase activities and 
possible related hormones in normolipemic men with severe and diffuse coronary 
atherosclerosis. 
Post-heparin plasma lipase activity has been shown to be lower in atherosclero-
sis, 19·20 but, no differentiation between lipoprotein lipase and hepatic lipase was 
made. The present paper suggests that hepatic lipase is lowered in male patients 
with diffuse coronary atherosclerosis, as compared to a group of control patients 
with no signs of coronary atherosclerosis. The implications of the present findings 
are not unequivocally clear. The lowered HL may be the result of the atherosclero-
tic process itself, However. this enzyme has been suggested to play a role in the 
removal of HDL-cholesterol from plasma,''-18·31 
Cholesterol may be mobilised from peripheral cells by HDL and transported to 
the liver. where it may be converted to bile acids.36 A lowered HL may impair this 
system and thus lead to a less efficient removal of cholesterol from the body and 
possibly to an enlarged body pool of cholesterol. Therefore, as has been suggested 
before, 30 a lowered HL may contribute to the progression of atherosclerosis. 
It has also been proposed that increased lipoprotein lipase may be atherogenic. 37 
Our results do not support this hypothesis. However, LPL originates from several 
tissues and local activities are not known. Recent studies have shown that HL is 
influenced by steroids. In men estrogens have been found to lower HL/5 while 
anabolic steroids increase HL.41 Hypercortisolism lowers HL.31 and as hypercorti-
solism can lead to hyperglucagonism, 38 an increased glucagon/insulin concentration 
ratio has been suggested to be responsible for the lower HL in atherosclerotic heart 
disease.3° For this reason we studied these hormones which are thought to be 
related to a lowered HL. The higher estradiol/testosterone ratio, the higher cortisol 
levels, and the higher glucagon levels in the study group may thus all have been 
contributing to the lowered HL. 
In conclusion, hepatic lipase was found to be lowered in male patients with 
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In conclusion, hepatic lipase was found to be lowered in male patients with 
diffuse coronary atherosclerosis. The underlying cause may be of endocrine origin 
as a result of a 'stress' -induced disregulation of HL by relatively higher levels of 
cortisol, glucagon or estradiol. It remains a subject for further study whether a 
lowered HL contributes to the origin of progession of coronary atherosclerosis or 
whether it is the result of the atherosclerotic process itself. 
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CHAPTER IV 
Diet, lipoproteins, and the progression of coronary 
atherosclerosis 
The Leiden Intervention Trial 
Alexander C. Arntzenius, M.D .• Daan Kromhout, Ph.D .• Jacques D. 
Barth, M.D., Johan H. C. Reiber, Ph.D., Albert V.G. Bruschke, M.D., Beert 
Buis, M.D., Coen N. van Gent, M.Sc., Noes Kempen-Voogd, R.D., Sipke 
Strikwerda, M.D., and Edo A. van der Velde, M.Sc. 
Summary 
We studied the relations between diet, serum lipoproteins, and the progression of 
coronary lesions in 39 patients with stable angina pectoris in whom coronary 
arteriography had shown at least one vessel with 50 per cent obstruction before 
intervention. Intervention consisted of a two-year vegetarian diet that had a ratio 
of polyunsaturated to saturated fatty acids of at least 2 and that contained less than 
100 mg of cholesterol per day. Dietary changes were associated with a significant 
increase in linoleic acid content of cholesteryl esters and a significant lowering of 
body weight, systolic blood pressure, serum total-cholesterol, and the ratio of total 
to high-density-lipoprotein (total!HDL) cholesterol. Angiographic examination 
was performed after 24 months; angiograms were assessed visually (with blinding) 
and by computer-assisted image analysis. Both types of assessment indicated 
progression of disease in 21 of 39 patients but no lesion growth in 18. Coronary 
lesion growth correlated with total!HDL cholesterol (r = 0.50, P = 0.001) but not 
with blood pressure, smoking status, alcohol intake, weight. or drug treatment. 
Disease progression was significant in patients who had values for total!HDL 
cholesterol that were higher than the median (>6.9) throughout the trial period. 
No coronary-lesion growth was observed in patients who had lower values for total/ 
HDL cholesterol (,;6.9) throughout the trial or who initially had higher values 
(>6.9) that were significantly lowered by dietary intervention. 
Introduction 
The Leiden Intervention Trial is a study of the effect of lowering cholesterol on 
coronary artery atherosclerosis. Most previous studies have shown that serum 
total-cholesterol can be lowered by changes in diet and by drugs, but have been 
inconclusive with respect to a reduction of the incidence of coronary heart disease. 1 
Recently, the Lipid Research Clinics Coronary Primary Prevention Trial has shown 
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that lowering of serum total-cholesterol and low-density-lipoprotein cholesterol by 
diet and cholestyramine was followed by a significant reduction in the incidence of 
coronary heart disease and death 2 ·3 An alternative strategy to evaluate the efficacy 
of lowering lipid levels is to measure the rate of change in arterial lesions as an end 
point.4 Eight studies of the latter type have been published.'-" In six of these, 
coronary arteries were evaluated by repeat arteriography, and in two, femoral 
arteries were examined. Atherosclerotic changes were shown to be associated with 
serum lipid levels in the two studies of femoral arteries and in four of the six studies 
of coronary arteries. In all eight trials intervention consisted of drug treatment, 
with or without diet. The Leiden Intervention Trial differs from these trials in that 
lipid levels were lowered solely by dietary measures. The objective of the study was 
to investigate the relations of diet and the ratio of serum total-cholesterol to high-
density-lipoprotein cholesterol (total!HDL cholesterol), to the growth of coronary 
lesions in patients with stable angina pectoris. 
Methods 
Patients with stable angina pectoris in whom coronary angiography had 
demonstrated severe narrowing of the diameter ("'50 per cent) of one of more 
major coronary arteries were selected for the triaL They had not undergone 
coronary bypass surgery, either because the angina was stable and only one of two 
vessels were diseased, or because the arteries were unsuitable for grafting and three 
vessels were diseased. The protocol excluded patients with disease of the left main 
coronary artery, coexisting valvular or nonischemic myocardial disease, or insulin-
requiring diabetes. Of the 61 persons, all under 60 years of age, invited to attend 
two introductory meetings with physicians and dietitians, 53 gave informed consent 
to enter the study. Full clinical examinations, including biochemical evaluation, 12-
lead electrocardiography, and measurement of weight and blood pressure, were 
carried out twice on two different days just before dietary intervention. The means 
of the values from these examinations were used as base-line readings. 
The trial was conducted from 1978 to 1982. Each patient followed a diet for two 
years, during which the usual, appropriate individual therapy was also given for 
angina pectoris, elevated blood pressure, cardiac arrhythmias, and symptoms of 
heart failure- e.g., betablockers, diuretics, digitalis, nitroglycerin, and anticoagu-
lants. The participants were seen 15 times during the two-year period by cardiolo-
gists and dietitians. Of the 53 patients who entered the study, 4 died during the first 
year- 3 of acute myocardial infarction and 1 suddenly. In seven patients with two-
vessel disease, the angina became labile and necessitated coronary surgery; this 
occurred in six of these patients in the first year of the study. The data for the seven 
patients were not used in analysis, since the angiographic techniques applied for 
their operations were not identical and since the rate of change of obstruction in 
grafted arteries is known to be different from that in ungrafted vessels. 13•14 Repeat 
37 
angiography was not carried out in three patients; malignant disease had developed 
in two, and the second investigation was refused by one. Thus, only data for 39 
patients could be used for analysis and are presented here. The 35 men and 4 
women were between 33 and 59 years of age (mean, 48.9). 
The study was approved by the Research Ethical Committee of Leiden Univer-
sity Hospital. 
Diet 
Intervention consisted of a vegetarian diet in which the ratio of polyunsaturated 
to saturated fatty acids (P/S ratio) was at least 2 and the dietary cholesterol was less 
than 100 mg per day. Much emphasis was placed on continuous supervision and 
dietary instruction for the patients and their spouses. Instruction was individualized 
and based on 24-hour recall of food intake, which was recorded before interven-
tion. To evaluate adherence one year after the trial had begun, we collected 
information on diet but were able to obtain it for only 28 of the 39 patients. It is 
unlikely that these 28 patients represented biased selection from among the 39, 
because at base line the food intake of the 28 did not differ significantly from that 
of 10 patients who participated in the base-line analysis only. The 28 patients 
weighted their food and drinks for one week under the supervision of a dietitian. 
All foods and drinks were coded and analyzed according to the Uniform Food 
Encoding System, recently developed in the Netherlands." 
Lipid Measurements 
Serum total-cholesterol and high-density-lipoprotein cholesterol were measured 
when the patients were not fasting, according to the method of Abell et a!. 
(Gaubius TNO Research Laboratory, Leiden). 16 High-density-lipoproteins were 
isolated by precipitating other lipoproteins with magnesium phosphotungstateP 
The fatty acid content of cholesteryl esters was analyzed by thin-layer and gas 
chromatography (Unilever Research Laboratory, Vlaardingen). For base-line 
readings, we recorded the mean of the two measurements made before interven-
tion, and for results at two years, the mean of the six measurements made during 
the trial. 
Coronary Angiography 
Coronary arteriography had been performed in ali patients immediately before 
entry. The initial visual assessment of the angiograms was conducted by a clinical 
angiographer (B.B.). Patients with at least one obstruction of 50 per cent or more 
were invited to enroll in the study. The examination was repeated, as scheduled, 
after two years of dietary intervention. The same technique (Judkins percutaneous 
femoral-artery approach) and the same radiographic equipment and cine-angio-
graphic techniques were used in obtaining the first and the second agiograms. With 
few exceptions, the procedure was performed by the same arteriographer (B.B.). 
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The angiograms were assessed both visually and by computerized image analysis. 
Films were assessed visually by two experienced observers who had no know-
ledge of the lipid values and who could not distinguish between the first and second 
angiograms since identical techniques had been used and since the dates of the 
films were concealed. They estimated the percentage of obstruction by each lesion 
in 30 segments of coronary arteries, in increments of 5 percentage points, as 
described by Bruschke et a!. 18 The severity of coronary lesions was scored by 
calculating the mean of the percentages of obstruction in each patient. 
Computer-assisted analysis was carried out with the computer-based Coronary 
Angiography Analysis System (CAAS, Thorax Center, Rotterdam). This system 
permits the accurate delineation of the contours of user-selected coronary arterial 
segments by means of automated edge-detection algorithms." Coronary lesions 
were measured in 9 segments of the major epicardial branches: the proximal, 
middle, and distal portions of the right coronary artery; the left main coronary 
artery; the proximal, middle, and distal portions of the left anterior descending 
artery (Figure 1.), and the proximal and distal portions of the left circumflex 
coronary artery. Since the accuracy of acquisition and measurement of an arterial 
vessel decreases when its diameter is less than 0.8 mm, side branches of the major 
epicardial arteries were not analyzed. 
The severity of coronary obstruction was expressed relatively, as the percentage 
of reduction of a vessel's diameter, and absolutely, as the minimal diameter (in 
millimeters) at the site of obstruction. We preferred the absolute value and used it 
throughout, since the relative value expresses the severity of the stenosis with 
respect to a user-defined reference position, whose location is arbitrary. Also, the 
reference diameter may change over time, thus possibly obscuring or 
overemphasizing the dimensional changes of the lesion. 
In order to evaluate the variability of the measurements, enddiastolic cine frames 
of 13 routine coronary angiograms were analyzed twice by one technician, with a 
median interval of 28 days between analyses. The average difference between 
duplicate measurements was found to be 0.00 mm; the variability, defined as the 
standard deviation of the differences between repeated measurements, was found 
to be 0.10 mm20 
Statistical Analysis 
Means and their standard deviations were used as descriptive statistics for the 
total group or subgroups of patients. Relations between continuous variables were 
analyzed by linear-regression analysis. Means were compared by the two-sample!-
test (two-sided) or, when appropriate, by paired t-test. Dichotomous variables 
were analyzed by the chi-square test. 
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FlGURE 1. 
Example of Computer Assessment of Obstruction of the Proximal Part of the Left Anterior Descending 
Artery (Right Anterior Oblique Projection). 
Detected contours are superimposed on the image. The ·diameter function' is presented in the lower 
left-hand section of the image; the minimal diameter at the site of obstruction equals 2.69 mm. and the 
percentage of diameter narrowing with respect to the user-defined proximal reference diameter equals 
37 per cent. The extent of the obstruction is indicated in the diameter function by the two dotted lines 
and in the arterial segments by the two lines connecting opposite contours of the vessel. 
Results 
Twenty-seven of the 39 patients with stable angina pectoris had previously had a 
myocardial infarction. At base line, 10 of the 39 patients had systemic hypertension 
(systolic blood pressure ;;, 160 mm Hg, diastolic ;;, 95 mm Hg, or both), 16 had 
hypercholesterolemia (cholesterol ;;, 7.2 mmol per liter [;;, 280 mg per deciliter]), 1 
was obese (Quetelet index> 27 kg per square meter of body-surface area), and 18 
were smokers. 
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At base line the diet contained an average of 2002 kcal per day, had a PiS ratio of 
0.91, and had a cholesterol content of 88.6 mg per 1000 kcal. In the Dutch 
population in general, the PiS ratio is 0.37 and dietary cholesterol is 140 mg per 
1000 kcal.21 These data suggest that the participating patients were already follo-
wing some type of cholesterol-lowering diet before they entered the study. They 
were then placed on the vegetarian diet with a PiS ratio of at least 2 and a dietary 
cholesterol intake of less than 100 mg per day. Compliance was measured by 
dietary surveys and by analyses of the serum linoleic acid content of the cholesteryl 
esters. The surveys showed that after one year of intervention the PiS ratio was 
2.54 and the dietary cholesterol intake 29.5 mg per 1000 kcal (Table I). These 
results indicate that the patients reduced their intake of saturated fat by about 50 
per cent and doubled their intake of polyunsaturated fat. The latter finding was 
confirmed by a significant increase- from 52.4 to 60.8 per cent- in the linoleic acid 
content of the serum cholesteryl esters. On the basis of changes in the fatty acid 
and cholesterol content of the diet, the expected decrease in average serum total 
cholesterol level could be calculated according to Keys· equation.22 The expected 
decrease did not differ from the observed (-D.79 vs. -D.82 mmol per liter [-30.5 vs. 
-31.7 mg per deciliter]). Body weight, Quetelet index, serum total-cholesterol, 
totai!HDL cholesterol, and systolic blood pressure dropped significantly during the 
intervention period (Table II). 
TABLE I 
Energy. fatty acids. and dietary cholesterol at base line and after one year of intervention in 28 ofthe 39 
patients.* 
Variable At base line At 1 year 
Energy (kcal) 2002 ± 518 2003 ± 581 
Saturated fat (% energy) 11.6 ± 4.8 6.6 ± 1.5 t 
Polyunsaturated fat (% energy) 8.5 ± 3.6 16.8 ± 4.2 i· 
PIS ratio 0.91 ± 0.62 2.54 ± 0.47 t 
Dietary cholesterol (mg/1000 kcal) 88.6 ± 23.5 29.5 ± 11.5 
Linoleic acid content of 
cholesteryl esters (%) 52.4 ± 6.2 60.8 ± 
* Values means ± S.D. PIS ratio denotes ratio of polyunsaturated fat to saturated fat. 
t Significantly different from base-line value (P<0.001). 
Coronary Artery Lesions 
4.0 
t 
t 
According to visual assessment, a total of 307 lesions (lowest degree of measured 
stenosis, 5 per cent) were detected in the 30 segments of coronary arteries. On 
average, the patient had 7.9±2.7 lesions. The mean percentage for diameter 
narrowing by the lesions was 44.1±31.6 per cent on the first arteriogram and 
48.6±30.9 per cent on the second, demonstrating a mean progression of disease in 
the 39 participants (P<0.001). 
According to computer assessment, a total of 166 lesions (of which the least 
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stenosis measured 0.14 mm) were detected in the 9 major epicardial coronary 
segments. On average, the patients had 4.26±1.521esions. Seven patients had one-
vessel disease, 11 had two-vessel disease, and 21 had three-vessel disease. The 
mean diameter of vessels at a total of 166 sites of obstruction was 2.12±0.99 mm on 
the first arteriogram and 1.99±1.01 mm on the second, illustrating, as also shown 
by visual assessment, that on average, the coronary lesions of the 39 patients 
progressed in the two years of observation (P<O.Ol). The four complete obstructi-
ons (100 per cent) seen at the first examination, which were slightly reduced at the 
second, were not included in the analysis, since recanalization was considered to be 
a different phenomenon. 
TABLE II 
Change in values for risk factors in the 39 patients over two years.* 
Risk factor At base line At 2 years Change 
Body weight (kg) 74.5 ± 11.4 73.5 ± 11.3 -1.2 ± 3.6 t 
Quetelet index (kg!m2) 24.0 ± 2.4 23.7 ± 2.6 -0.4 ± 1.1 t 
Serum total-cholesterol 
(mmollliter) t 6.9 ± 1.4 6.2 ± 1.3 -0.7 ± 0.7 § 
HDL-cholesterol 
(mmol/liter) t 1.01 ± 0.21 0.98 ± 0.16 -0.03 ± 0.14 
TotaJJHDL-cholesterol 7.1 ± 1.8 6.4 ± 1.6 -0.6 ± 1.2 ~ 
Blood pressure (mrn Hg) 
Systolic 130.4 ± 17.4 126.3 ± 14.2 -4.2 ± 11.2 j· 
Diastolic 84.4 ± 11.1 82.1 ± 7.6 -2.4 ± 8.5 
Smoking (no. of patients) 18 18jj 0 
Values are means ± S.D. 
t Significant difference (P<O.OS). 
:j: To convert to milligrams per deciliter. multiply by 38.7. 
§ Significant difference (P<0.001) 
,-r Significant difference (P<O.Ol) 
II Includes four patiens who stopped smoking during the second year of intervention. 
Progression of Coronary Lesions 
Progression of lesions was defined as a decrease of 0.1 mm or more in the mean 
coronary diameter (computer assessment) or as an increase in the mean percentage 
of narrowing (visual assessment). Both visual and computer-assisted assessments 
showed progression in 21 of the 39 patients but no lesion growth in 18 patients. The 
degree of reduction of total-cholesterol (1.1 mmol per liter) and tota!JHDL-
cholesterol (1.0) was greater in patients with progression of a lesion than in those 
without progression (0.6 and 0.1 mmol per liter, respectively). However, the 18 
patients with no progression of coronary lesions had significantly lower values for 
total-cholesterol and totaVHDL-cholesterol and higher values for high-density-
lipoprotein cholesterol both at base line and during the two years of intervention 
(Table III). No difference were found between these two groups with respect to 
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age, smoking status, alcohol intake, systolic or diastolic blood pressure, Quetelet 
index, or fatty acid composition of the diet at base line or during intervention. 
Also, the use of anticoagulants, beta-blocking agents, digitalis, diuretics, and 
nitroglycerin was unrelated to progression of coronary lesions. Since patients 
entered the trial with at least one 50 per cent obstruction, progression of major 
obstructions (;.50 per cent) was analyzed separately from that of minor lesions 
(<50 per cent). A mean progression of -4.29 per cent occurred in the 124 minor 
lesions, and a mean regression ( +3.47 per cent) took place among the 42 major 
obstructions. 
TABLE III 
Relation between coronary lesion growth (computer assessment) and total-cholesterol. HDL-choleste-
rol. and total!HDL-cholesterol at base line and after two years of intervention.* 
No growth Lesion growth 
(18 patients) (21 patients) 
Total-cholesterol (mmol/liter) t 
At base line 6.4 ± L1 7.4 ± 1.5 t 
At 2 years 5.8 ± 0.9 6.5 ± 1.5 t 
HDL-cholesterol (mmolJliter) t 
At base line 1.1 ± 0.2 0.9 ± 0.2 t 
At 2 years 1.0 ± 0.1 0.9 ± 0.2 t 
Total!HDL-cholesterol 
At base line 5.8 ± 1.2 8.1 ± 1.7 § 
At 2 years 5.7 ± 1.2 7.1 ± 1.7§ 
Values are means± S.D. 
t To convert to milligrams per deciliter. multiply by 38.7. 
:j: Significantly different from value for patients with no lesion growth (P<O.Ol). 
§ Significantly different from value for patients with no lesion growth (P<O.OOl). 
Correlation between Values for Total/HD L-Cholesterol and Coronary Lession 
Growth 
Computer-measured lesion growth correlated positively with the mean of values 
for total/HDL-cholesterol at two years (r = 0.39, P = 0.01); visual assessment 
showed a positive association between these features that was of the same 
magnitude (r = 0.38, P = 0.02). When the coronary obstruction that was the largest 
but was less than 99 per cent (the obstruction that qualified a patient to enter the 
trial) was measured, the correlation between lesion growth and total/HDL-choles-
terol was again of the same magnitude (computer assessment: r = 0.38, P = 0.02). 
Coronary lesion growth, no matter by what technique it was measured, proved to 
be even more strongly correlated with base-line totaVHDL-cholesterol (computer 
assessment: r=0.55, P<O.OOl) and the average of base-line and two-year means 
(r=O.SO, P=0.001) (Figure 2). 
This finding prompted us to look at the difference in base-line characteristics 
between the 19 'low' patients- i.e., those whose totaVHDL-cholesterol was lower 
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than the median ( <6.9) - and the 20 'high" patients - those with higher values 
(>6.9). At base line the 20 high patients consumed on average 350 kcal per day 
more than the 19 low patients (P<0.05). but the groups did not differ in fatty acid 
content of the diet. blood pressure. weight. smoking status. or number of severity 
of coronary lesions (Table IV). Over the ensuing two years the mean coronary 
diameters of the 19 low patients remained the same (mean change. +0.002 mm). 
but those of the 20 high patients showed significant disease progression (mean 
change. -0.237 rnm). 
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FIGURE 2 
Association between change in coronary lesion and ratio of total to high-density-lipoprotein (total/ 
HDL) cholesteroL according to individual patient (computer assessment). 
Values for total!HDL-cholesterol are averages of base-line and mean two-year values for 39 patients. 
Progression of lesion growth (values above 0.1 mm) is associated with relatively high values for total/ 
HDL cholesterol (2 patients). Mainly. patients with relatively low values for total!HDL-cholestcrol had 
no disease progression - some even had regression. 
Diet. Total/HDL-Cholesterol, and Coronary Lesion Growth 
Because there was no control group. the effect of dietary intervention on 
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lipoprotein levels and coronary lesion growth could not be assessed directly. To 
obtain indirect information on the effect of the diet, the data were stratified 
according to the 'low' and 'high' patient groups. In addition, the 20 high patients 
were divided in two subgroups: 'the 'high-high' subgroup- 11 patients whose total/ 
HDL cholesterol remained high during the two years of intervention - and the 
'high-low' subgroup - 9 patients whose ratio became low over the two years. 
TABLE IV 
Relation between serum total/HDL-cholcsterol at base line and characteristics of coronary lesions at 
base line and after two years of intervention.* 
Lesions/patient 
Visual assessment 
Computer assessment 
Vessel diameter (mm) t 
At base line 
At 2 years 
Change in vessel diameter 
Absolute (mm) 
Relative (%) 
Values are means ± S.D. 
t Computer assessment. 
Total/HDL-cholesterol at base line 
~6.9 >6.9 
(19 patients) (20 patients) 
7.74 ± 2.80 
4.37 ± 1.74 
2.15 ± 0.58 
2.15 ± 0.61 
0.002 ± 0.23 
2.2 ± 5.8 
8.15 ± 2.76 
4.15 ± 1.31 
2.30 ± 0.47 
2.07 ± 0.45 
- 0.237 ± 0.32 * 
-5.0 ± 6.7 § 
:j: Significantly different from value for patients with ratio ~6.9 (P<O.Ol). 
§ Significantly different from value for patients with ratio ~6.9 (P<O.OOl). 
The fatty acid and cholesterol content of the diet was expressed as the so-called<!> 
(phi) value, bases on Keys' equation22 : 
<!> = (2S - P) + 1.5 vz, 
where S denotes saturated fatty acids (per cent energy), P polyunsurated fatty acids 
(per cent energy), and Z dietary cholesterol (milligrams per 1000 kcal) (Figure 3). 
The values for saturated fatty acids and cholesterol content elevate the <!> value, 
whereas the value for polyunsaturated fatty acids does the opposite. At base line in 
the present study the highest<!> value (45.3) was found"among the nine high-low 
patients: it was closest to that of the Dutch population (60.0) 21 The base-line<!> 
values of the low group and the high-high subgroup were lower (35.8 and 31.4, 
respectively). After one year of intervention, no difference between the<!> values of 
the three groups were observed. The change in the <!>value (resulting from a lower 
saturated-fat and cholesterol intake) was largest in the rrine persons in the high-low 
group (P<0.05). No progression of coronary lesions (mean change, -0.043 mm) 
was observed in these nine patients (Figure 3). However, the coronary arteries of 
the 11 high-high patients showed considerable and significant progression of 
disease (mean change in diameter, -0.396 mm; P = 0.01). These findings suggest 
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that in patients with high values for toai!HDL-cholesterol and high c;!> values, the 
possibilities for benefit from intervention are greater than in patients with low 
values. 
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Association between change in coronary lesion and total/HDL-cholesterol. according to patient group 
or subgroup. 
Values for <I> (content of fatty acids and cholesterol in diet, based on Keys' equation12) are also 
presented according to group. Values at base line are denoted by 0. and mean values at two years by 2: 
in the low group they are 5.52 and 5.40, respectively; in the high-low subgroup. 7.79 and 6.17: and in the 
high-high subgroup, 9.16 and 8.46. Disease progression occurred in the high-high subgroup. but not in 
the low group or the high-low subgroup (t = 2.87. P = 0.01). 
Discussion 
The purpose of the Leiden Intervention Trial was to analyze the relations of diet 
and totai!HDL-cholesterol to coronary lesion growth as assessed angiographically. 
Fifty-three patients with stable angina were enrolled in the study, but data on 14 (7 
underwent grafting, 4 died, 2 had neoplasms, and 1 refused repeat angiography) 
could not be used for analysis. This loss of a quarter of the patient population 
weakened the study results, but the 14 patients' base-line status for risk factors did 
not differ from that of the 39 who could be evaluated. 
It should be pointed out that coronary lesion growth itself cannot as yet be 
measured. We used the term only for brevity's sake. The change in coronary 
diameter was the variable that we estimated. This variable is not specific for 
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atherosclerosis and may be influenced by other biologic variables, such as vascular 
tone. We used two different and independent techniques, computer assessment 
and visual assessment. With visual assessment 307 lesions were detected in all 
segments of coronary arteries, or roughly 10 lesions per segment. The computer 
technique measured 166 lesions in the 9 major epicardial segments, or roughly 18 
lesions per segment. This is in keeping with the fact that major branches generally 
have more lesions than smaller branches. The visual and computer techniques 
produced a similar - i.e., the finding that 18 of the 39 patients had no coronary 
lesion growth. Also, the correlation between values for total!HDL-cholesterol and 
coronary lesion growth was similar on computer assessment (r=0.39, P=0.01) and 
on visual assessment (r=0.38, P=0.02). These results give the study an internal 
consistency. 
Tota/!HDL-Cho/esterol and Coronary Lesions 
The results of the study suggest that the values for total!HDL-cholesterol in the 
39 patients with stable angina were associated with lesion growth of coronary 
atherosclerosis, as assessed either by a computer-assisted technique or visually. 
This relation was noted for lipid levels at two years as well as for base-line total/ 
HDL-cholesterol. The association was stronger for base-line values, possibly 
because the range of values for total!HDL-cholesterol (95 cent of values between 
3.46 and 10.68) was larger at base line than during the two years of intervention 
(3.32 and 9.56), since all patients were put on the same diet (Table I). A strong 
correlation was observed between total/HDL-cholesterol at base line and at two 
years (r = 0.78, P<0.001). We therefore conclude that in the present study 
coronary lesion growth was strongly related to the total!HDL-cholesterol. Previous 
intervention studies aiming at lowering lipids, notably clinical trials by Kuo (1979), 
Nash (1982), Nikkila (1983), and Levy (1984) and their colleagues, also 
demonstrated associations between serum cholesterol levels and the likelihood of 
progression of coronary atherosclerosis lesion growth as assessed by repeat coro-
nary arteriography.s.12• 
In the present study no lesion growth was observed in the patients with low total! 
HDL-cholesterol at base line ( ~6.9) that was reduced by 2 per cent during two 
years of intervention. Similar results were obtained in patients with high total! 
HDL-cholesterol at base line (>6.9) that was reduced by 13 per cent- to below 6.9 
- during intervention. Patients with initially high total/HDL-cholesterol that was 
eventually reduced by 8 per cent only and that stayed above 6.9 had significant 
disease progression (Figure 3). The question whether coronary lesion growth 
among these patiens was less than among untreated patients with high total!HDL-
cholesterol cannot be answered, because a control group was lacking. Lack of a 
control group complicated the analysis and interpretation of the results of the 
present trial. It is possible that the relation between total/HDL-cholesterol and 
lesion growth can be explained by other risk factors. Information was collected on 
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blood pressure, smoking status, alcohol intake, weight (Quetelet index), and drug 
treatment- e.g., anticoagulants, beta-blockers, diuretics, digitalis, and nitroglyce-
rin. Coronary lesion growth was unrelated to these risk factors. This strengthens 
the conclusion that totai/HDL-cholesterol was related to coronary lesion growth, 
although the possibility that some unidentified risk factor may a part cannot be 
definitely ruled out. 
Diet, Total/HDL-Cholesterol, and Coronary Lesions 
In intervention studies, information on compliance with diet is crucial. In the 
Leiden trial, compliance with the vegetarian, linoleic acid-enriched diet was 
measured by dietary surveys and by analysis of the linoleic acid content of 
cholesteryl esters. Dietary data could be obtained at base line in 38 of 39 patients 
and at one year of intervention in 28 patients. The base-line energy and nutrient 
intake of the 10 patients who did not participate in the second survey did not differ 
from that of the 28 participating patients. Comparison of the base-line and one-
year data showed a significant increase in the P/S ratio, from 0.91 to 2.54. The 
increase in dietary linoleic acid in the 39 patients was confirmed by a significant 16 
per cent increase in linoleic acid content of cholesteryl esters. These results indicate 
that patients adhered well to the diet. The finding that the observed mean decrease 
in total serum cholesterol (-0.82 mmol per liter) did not differ from the expected 
value as calculated by Keys' equation (-0.79 mmol per liter) provides evidence for 
the validity of the dietary information collected among these patients. 
To obtain information about the efficacy of the dietary intervention, the 39 
patients were divided into three groups bases on their values for totai/HDL-
cholesteroi. In the 19 patients with low values at base line and the 9 patients with 
high values at base line but low values during intervention, coronary artery lesions 
were stable. The 11 patients with high values throughout the trial had significant 
disease progression. The <!> value of the diet at base line was high among the 
patients whose values for totai/HDL-cholesterol were high at base line and low 
during intervention. The <!> value was low among the patients in the two other 
groups. These results suggest that when totai/HDL-cholesterol is low in patients 
with angina, their prospects with respect to coronary lesion growth are favorable. 
When totai/HDL-cholesterol is high and the <!>value before intervention is rather 
low, coronary lesions are likely to progress. When, however, totai/HDL-choleste-
rol is high and the <!> value of the fatty acid and cholesterol content of the diet is also 
high (e.g., similar to values in the general population of industrialized Western 
countries), dietary intervention may reduce the rate of coronary lesion growth. 
Further research should be directed toward early indentification of patients with 
high values for totai/HDL-cholesterol and<!>, in whom dietary intervention may be 
successful, as well as patients with equally high totai/HDL-cholesterol but low <!> 
values - a group to which most of the heterozygous patients with familial hyper-
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cholesterolemia undoubtedly belong and in which diet alone is insufficient to 
prevent progression of coronary atheroslcerosis. 
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Summary 
CHAPTER V 
Quantitative Coronary Angiography 
in a Lipid Intervention Study 
The Leiden Intervention Trial 
Postheparin lipoprotein lipase activities, lipid fractions and atherosclerosis linked 
hormones were studied in 35 male patients with advanced coronary artery disease, 
who participated in a two year diet only, lipid lowering intervention program, The 
Leiden Intervention Trial. Sequential angiographies, one at the beginning of the 
trial and one two years later, were performed to assess the degree of progression or 
regression of the disease; the coronary angiograms were analyzed with the Cardio-
vascular Angiographic Analysis System 'CAAS', In each patient film a total of nine 
coronary segments in the major coronary arteries were analyzed in at least two 
angiographic views. From the obstruction diameters and mean diameter values in 
nonobstructed segments, an absolute coronary score was derived. A patient was 
considered to have progressive disease, if the absolute coronary score showed a 
decrease over the study period. No lesion growth or regression of the disease was 
assumed if the coronary score showed an increase. Specific response patterns to 
dietary therapy were measured for total cholesterol, triglycerides, HDL-cholesterol 
and the postheparin lipases, sex-, and thyroid hormones, insulin and cortisol. 
At termination of the study fourteen men showed no lesion growth or regression 
of atherosclerosis, whereas twenty-one men showed further progression of their 
underlying disease. Lipoprotein lipase (LPL) was not significantly different in the 
two groups studied, while liver lipase activity (LLA) was significantly lower 
(p < 0.001) in the progression group (298 ± 190 mU/ml) as compared to the no 
lesion growth group; ( 499 ± 146 mU/ml) LLA was inversely correlated with the 
degree of progression. (r = - 0.601, p < 0.01); Cholesterol and triglycerides 
were higher and HDL-cholesterollower in the progression group as compared to 
the no lesion growth group. The measured hormones, testosterone, estradiol- 1713, 
cortisol, insulin, thyroid stimulating hormone, thyroxine and TTresin uptake were 
not different between the two groups of patients. Triiodothyronine (T3) appeared 
to be significantly higher in the no lesion growth group. (2.24 ± 0.36 vs. 1.86 ± 
0.28) Linear regression analysis showed a poor correlation between LLA and T3• 
(r = 0.283, p = n.s.) When the individual responses to dietary intervention 
were assessed, LLA appeared to be an important indicator of an inducibility of 
regression of atherosclerosis by dietary means. 
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We infer from this study, in which for the first time a lipid lowering diet therapy 
in coronary atherosclerosis was prescribed, in which sequential coronary angie-
grams were analyzed quantitatively and in which atherogenesis linked hormones,li-
pid fractions and lipoprotein lipases were measured, the following: 
L Regression of coronary atherosclerosis due to dietary therapy appears to be 
feasible. 
2. Liver lipase activity is a possible-marker for the success of dietary intervention 
to induce a deceleration of the natural course of coronary atherosclerosis. 
3, Testosterone, estradiol, thyroxine, thyroid stimulating hormone, cortisol and 
insulin seem to be of no great additional importance, when lipid fractions are 
manipulated by dietary means to induce regression of coronary atherosclerosis. 
The triiodothyronine level seems to reflect the body's metabolic status and adds 
an additional aspect, if raised as to the presence of regression of coronary 
atherosclerosis. 
Introduction 
Coronary atherosclerosis resulting in angina pectoris, myocardial infarction and 
sudden death remains a major contributor to the epidemic of cardiovascular 
disease in the industrialized world. 1 One of the major factors that determine the 
rate of development of progression of coronary atherosclerosis is a disordered lipid 
metabolism. 2-5 
The total cholesterol (TC) is considered to be causal to coronary artery disease 
(CAD) for the reasons as stated by the WHO Expert Committe on the Prevention 
of Coronary Heart Disease:' 'The manifestation of its strength, graded character, 
consistency and independence, the demonstration that the trait precedes the 
disease: the coherence with clinical and experimental data: and the fact that logical 
mechanisms have been deliniated for the effect'. 
The major lipid fraction within TC is the low-density-lipoprotein (LDL) fraction. 
This fraction has been implicated as the 'atherogenic' fraction, while another 
lipoprotein fraction, the high-density-lipoprotein (HDL), has been considered as 
'anti-atherogetic' for many reasons, among these the inverse relationship to 
coronary atherosclerosis and its clinical manifestations. 7 Modulaters of lipoprotein 
metabolism, that codetermine the ratio between 'good' (HDL) and 'bad' (LDL) 
cholesterol are therefore of great importance. Postheparin lipoprotien lipase 
activiteis are important modulators in the process of atherosclerotic develop-
ment. S-12 Another group of factors that influence directly or indirectly this process 
are centain hormones, e.g. the sex-, thyroid- and stress-hormones. 1J-..17 
Until recently only more or less specific clinical manifestations of the atheroscle-
rotic lesion growth, such as angina pectoris, acute myoccardial infarction or sudden 
death, could be studied. It is also well-known that a direct positive relationship 
exists between the number of vessels diseased and the level of the ratio of total-
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cholesterol to HDL-cholesterol. 18 However, an accurate method to study growth or 
possibly regression of atherosclerotic plaques itself, which is strongly related in 
living human subjects to the clinical manifestations mentioned above, was un-
available. 
Visual interpretation of sequential coronary angiographies was one method by 
means of which one has tried to measure directly the natural growth of coronary 
atherosclerosis in humans. By this means one did not want to wait for manifestati-
ons of atheroclerosis, but attempted to observe the process of growth itself. 
However, the method of visual interpretation is very much limited by the relatively 
large inter- and intra-observer variations in the judgement of the serverity of the 
disease; these variations in itself are usually larger than the absolute anatomical 
changes present in the serial angiograms. 19-21 
With the CAAS, differences in the atherosclerotic plaques between two sequen-
tial angiograms can be measured with high accuracy. To demonstrate the applicabi-
lity and the value of the CAAS in such studies, the coronary angiograms in the 
Leiden Intervention Trial were measured with this system.22 
Methods 
Patients 
Thirty-five male patients with chronic stable angina pectoris who had undergone 
coronary arteriography to assess their suitability for coronary bypass grafting 
surgery were selected for the study after having been rejected for surgery for 
technical reasons.22 They were offered to participate in a diet intervention study. 
At the end of the two year study period a repeat coronary arteriography was 
performed. 
Although both sexes could be admitted according to the original design of the 
study, in practice ouly four women entered the study. As postheparin lipoprotein 
lipase activities and hormone levels differ between the sexes, only the 35 men who 
completed the study were ultimately evaluated. The study lasted from 1978 until 
1982 and each patient was on dietary intervention for a period of 2 years, with -if 
needed - individual therapy for angina pectoris or hypertension. 
All patients were seen monthly during the first half year at the outpatient clinic 
and bimonthly thereafter. They were seen by a cardiologist and a dietician for a 
total of fifteen times during the two year period. At each visit lipid fractions were 
measured, and a routine physical examination and dietary re-evaluation were 
performed. 
Diet 
A diet advice was given to all patients participating in the study and active 
encouragement to comply with this advice was also give to the partners of the 
patients. The diet was vegetarian with a total fat content of 34 energy( cal) percent 
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(e%) with allow saturated fat content of7.0e%. It contained 100 mg cholesterol or 
less and was low caloric, if appropriate. Adherence to the diet was assessed by the 
determination of the fatty acid content of cholesterol esters. 
Dietary instruction was individualized and based on a 24 hour recall which was 
carried out in the first weeks following study admittance. Adherence to the diet 
was further checked by evaluation of the food consumed during a period of one 
week. Further measures that were undertaken to try to mitigate coronary risk 
factors were the following. Smoking was strongly discouraged. An advice to 
exercise at least half an hour daily was given. Hypertension (RR;;.160/95 mmHg) 
if present, was treated with hygienic methods; if this failed, a step-up medication 
was prescribed consisting of beta-blocking agents, diuretics, and vasodilatingdrugs. 
Biochemical measurements 
Serum total cholesterol (TC) and HDL-cholesterol (HDL-C) were determined 
at the Gaubius TNO Research Laboratory in Leiden in accordance with Abell's 
method.23 HDL-C was isolated by precipitating other lipoproteins with magnesi-
umphosphotungstate; cholesterol was determined in the supernatant. 24 
Baseline readings were defined by the mean values of the measurements on two 
different days prior to entry into the study; for the interpretation of the results due 
to the intervention, the mean values of the total of fifteen measurements perform-
ed over the following two years were determined. 
Triglycerides were measured at the end of the study following an overnight fast 
in a basal resting state. 25 Also at the termination of the study, postheparin 
lipoprotein lipase activities - liver lipase activity (LLA) and lipoprotein lipase 
(LPL) - were measured as follows: Thirty minutes after introduction of an 
intravenous catheter in the right brachial vein, heparin (50 IU/kg bodyweight) was 
administered intravenously. Blood was collected from the left brachial vein in 
disodium EDTA (2.7 mmol/1) on ice. Twenty minutes after the administration of 
heparin, blood was centrifuged at 4° C for 30 minutes at 3000 r.p.m. and plasma 
was stored at -20°. LPL and LLA were measured at the Department of 
Internal Medicine HI of the Erasmus University Rotterdam.26 
At the end of the study hormone measurements were performed in blood drawn 
30 minutes after introduction of an intravenous catheter prior to heparin admini-
stration according to the following methods: cortisol (C), estradiol 17~ (E2)/7 
testosterone (T),28 triiodothyronine (T3),29 thyroxine (T4),30 T,-resin-uptake,29 thy-
roid stimulating hormone (TSH),30 and insulin (In). 
Quantitative coronary arteriography 
The coronary angiographic investigation was performed at the Department of 
Cardiology of Leiden University via the Judkins technique. The initial and sequen-
tial coronary arteriographies were performed by the same angiographer. At the 
second arteriography special care was taken to obtain projections identical to those 
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of the first angiography. At the time of the first angiography the angulations of the 
X-ray systems in the different projections had been registered. Angiograms were 
recorded on 35 mm cinefilm using the 6 inch mode of a Philips image intensifier. 
All patients had constant dose maintenance therapy, thereby reducing possible 
effects on diameter measurements due to a change in vasomoter tone. 
Quantitative analysis of coronary arterial segments was carried out with the 
CAAS at the Thoraxcenter in Rotterdam. An example of the quantitative analyses 
of the pre- and post-intervention coronary angiograms is shown in Figure.l. The 
severity of a coronary obstruction was expressed as a percentage diameter reduc-
tion with respect to a user-defined reference position proximal or distal to the 
stenosis and by means of the absolute value of the minimal obstruction diameter. 
For arterial segments showing no focal obstruction the mean diameter value over a 
user-defined length was computed. 
Cineframes to be analyzed were selected as closely as possible to the end-
diastolic phase. In cases of overlap of a particular segment with other vessels, a 
frame was selected at another instant in time. 
FIGURE 1 
Example of quantitative results of one particular coronary segment (proximal part of right coronary 
artery) in the pre- and post-study situation. Note that a decrease of approximately 0.1 mm in the 
minimal obstruction diameter was found at the end of the study (obstruction diameter 3.08 mm) as 
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Coronary angiographic scoring method 
The large coronary arteries were divided into a total of nine coronary segments 
according to the recommendations by the American Heart Association (right 
coronary artery: proximal, mid and distal portions; left anterior decending artery: 
proximal, mid and distal portions; left circumflex artery: proximal and distal 
portions; and the main-stem, 31 These nine coronary segments were analyzed in at 
least two angiographic views. For each analyzed coronary segment the severity of 
an obstruction, if present, was computed in terms of relative and absolute measures 
in addition, the mean diameters over the remaining normal proximal and distal 
parts were computed. From all data two coronary scores were derived, a percen-
tage coronary score and an absolute coronary score; an example is given Table I. 
The percentage score was determined as follows: for each obstruction the percen-
tage area stenosis was computed from the percentages diameter stenoses assessed 
from two projections, assuming elliptical cross sections, and multiplied by a flow 
dependent weighting factor specific for that particular coronary segment. 32 The 
total percentage coronary score was by adding these weighted area stenosis values 
for all obstructions in the nine coronary segments. 
compared to the initial situation (obstruction diameter 3.18 mm). Due to the fact that the reference 
diameter showed a larger decrease in size than the obstruction diameter. the percentage diameter 
stenosis decreased as well from 40% to 31%. 
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TABLE I 
Example computation of percentage and absolute coronary scores. 
Percentage coronary score 
Analyzed lesion Pre-study Post-study 
Branch Section %-A sten. WF Cor. score %-A sten. WF Cor. score 
RCA mid 1 0.31 1.0 0.31 0.23 1.0 0.23 
RCA mid2 0.15 1.0 0.15 0.39 1.0 0.39 
RCA mid 3 0.89 1.0 0.89 0.88 1.0 0.88 
RCA mid 4 0.87 1.0 0.87 0.78 1.0 0.78 
LAD prox 0.64 3.5 2.24 0.53 3.5 1.86 
LAD mid 1 0.93 2.5 2.33 0.91 2.5 2.28 
LAD mid 2 0.92 2.5 2.30 0.90 2.5 2.25 
LCX dist 1 0.45 1.0 0.45 0.42 1.0 0.42 
LCX dist 2 0.73 1.0 0.73 0.45 1.0 0.45 
Total 10.27 Total 9.54 
Mean obstr. diameter Pre Post Mean diameter Pre Post 
art. segm. 
RCA 2.50 2.11 RCA 3.59 3.54 
MAIN MAIN 4.66 4.27 
LAD 1.65 1.75 LAD 2.77 2.80 
LCX 2.21 2.22 LCX 3.42 3.01 
Absolute coronary score (mm) 
Pre Post 
RCA 2.50 2.11 
MAIN 4.66 4.27 
LAD 1.65 1.75 
LCX 2.21 2.22 
+ 
Absol. score 11.02 10.35 
Abbreviations: RCA: right coronary artery; LAD: left anterior descending artery: LCX: circumflex 
artery: %-A sten: percentage area stenosis computed from the measured percentages diameter 
stenosis in two views: WF: flow dependent weighting factor. 
The absolute coronary score was determined as follows: for each of the four 
large coronary arteries mentioned above the mean obstruction diameter in mm was 
computed from the available views. If no obstruction was present in a coronary 
artery, the mean value of the computed average diameter measurements for the 
different segments of this artery was substituted. Adding these 4 mean diameter 
values resulted in the absolute coronary score. The changes in the percentage and 
absolute coronary scores over the two year diet period were simply determined as 
the differences in the pre- and post-diet coronary scores. 
A patient was considered to have progressive disease, if the absolute coronary 
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score showed a decrease. No lesion growth or regression of the disease was 
assumed if the coronary score showed an increase. Since we were particularly 
interested in changes of absolute dimensions of coronary obstructions and of 
nonobstructed segments, only absolute measurements were used for this study. 
Statistical Analysis 
Mean values and their standard deviations were used as descriptive statistics for 
the total group of subgroups of patients. Mean values were compared by the two 
sample t-test (two-sided) or when appropriate by paired t-tests. Relations between 
continuous variables were analyzed by linear regression analysis. All results are 
expressed as mean ± standard deviation (x±s.d.). Multivariate analysis was 
performed by stepwise discriminant analysis. 33 
Results 
No significant difference was found in the initial coronary scores between the no 
lesion growth group of patients (n=l4) and the progression group (n=21) 
(Table II;) neither were weight, age, blood pressure or smoking habits significantly 
different. Persistance of anginal complaints in the progression group was much 
higher than in the no lesion growth group. 
TABLE II 
Clinical data and coronary scores in patients showing no lesion growth and those with progression of 
coronary atherosclerosis. 
Age (years; X± s.d.) 
Number of patients 
Smoking 
Angina pectoris 
Syst. BP (mmHg; mean) 
Diast. BP (mmHg; mean) 
Quetelet index (kg/m2; mean) 
CS (mm; mean ± s.d.) 
D..CS (mm; mean± s.d.) 
No lesion growth group 
(n ~ 14) 
49.8 ± 8.0 
Pre-study Post-study 
9 ( 64%) 6 (42%) 
14 (100%) 6 (42%) 
130 124 
83 80 
23.9 23.9 
10.17 ± 1.72 11.14 ± 1.79 
+ 1.02 ± 0.69 
Progression group 
(n ~ 21) 
52.4 ± 7.8 
Pre-study 
10 ( 48%) 
21 (100%) 
131 
85 
Post-study 
5 (23%) 
17 (80%) 
128 
85 
24.1 23.4 
10.38 ± 2.29 9.17 ± 2.12 
- 1.20 ± 0.96 
Abbreviations: n. number of patients; BP. blood pressure; CS, coronary score; D..CS, the difference 
(mm) in absolute coronary scores between the pre- and post-study angiograms. 
In Table III the pre- and post-study values of several lipid fractions and of the 
postheparin lipoprotein lipase activities are given for both groups of patients. At 
the start of the intervention trial total-cholesterol (TC) was significantly higher in 
the progression group, while high-density-lipoprotein cholesterol (HDL-C) was 
almost the same in both groups. At the end of the study a significant difference was 
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observed in the triglycerides (TG) values. TC levels showed a relatively larger drop 
in the progression group than in the no lesion growth group (although not 
significant). Liver lipase activity (LLA) in the progression group was significantly 
lower than in the no lesion growth group of patients, while lipoprotein lipase (LPL) 
was not different in the two groups of patients. LLA was inversely correlated with 
the degree of progression in the total population (Figure 2). LPL did not show any 
significant linear regression relation to the changes in coronary scores of the total 
population. Multivariate stepwise discriminant analysis showed LLA to be the 
most powerful parameter to progression or regression of atherosclerosis, indepen-
dently from other pre- or post-study parameters (TC, HDL-C, TG). The change in 
the degree of coronary atherosclerosis expressed in terms of differences in absolute 
coronary scores, was not related to the change in TC or to the change in the TC to 
HDL-C ratio (r= -0.196) (Figure 3). 
TABLE III 
Serum lipids and lipases in patients showing no lesion growth and those with progression of coronary 
atherosclerosis. 
TC 
HDL-C 
TG 
LLA 
LPL 
No lesion growth group 
(n = 14) 
Progression group 
(n = 21) 
Pre-study Post-study Pre-st,udy 
r------ p < 0.05-----, 
6.37 ± 1.05 
·•· 5.80 ± 1.03 7.22 ± 1.57 _,._ 
Post-study 
6.43 ± 1.55 
'------P < 0.05-----.J 
1.00 ± 0.15 1.01 ± 0.19 
1.59 ± 1.14 
499 ± 146 
86 ± 36 
0.99 ± 0.11 0.96 ± 0.11 
__ ,. __ _ 
___ .,..,.,. __ _ 
2.02 ± 1.04 
298 ± 190 
87 ± 34 
Abbreviations: TC: total-cholesterol (normal values: 4.5-8.0 mmolll)~ HDL-C: high-density-lipopro-
tein-cholesterol (normal values: 0.80-1.20 mmol/1): TG: triglycerides (normal values: 0.50-2.50 mmol/ 
19: LLA: liver lipase activity (mU/ml) (normal values: 472 ± 127): LPL: lipoprotein lipase (mU/ml) 
(normal values: 87 ± 32): 1 mU = mmoles free acids released/min. All values are mean ± s.d.: 
* p < 0.05: ** p < 0.01: *** p < 0.001. 
Table IV shows the absence of any significant difference in basal cortisol, 
estradiol-17[3, testosterone and insulin values between the no lesion growth and 
progression groups of patients. Similarly, there were no significant differences in 
for, T,-resin-uptake and the thyroid stimulating hormone between these two 
groups of patients (Table V). However, triiodothyronine (T3), appeared to be 
significantly (p<0.01) higher in the no lesion growth group, thyroxine (T4) was 
lower in the no lesion growth group (p < 0.01) although T3 and T4 remained 
within the normal ranges for both groups. Linear regression analysis showed a poor 
correlation between LLA and T3 (r = 0.283, p = n.s.). 
When the total male population was categorized according to the lipid lowering 
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CHANGE IN CORONARY SCORE (rnrn) 
FIGURE 2 
n = 35 
r : - 0.601 
y : 390-8!.5X 
p < 0.01 
-3.0 
This figure shows the relationship between the change in absolute coronary score (mm) and liver lipase 
activity at the end of the study period. LLA = liver lipase activity (mU/ml), 1 mU = mmoles free fatty 
acids released/min. 
effects of the diet, three response patterns became apparent (Table VI). The group 
(n = 15 patients) with an initial low TC to HDL-C ratio (~ 6.9) remained so 
during dietary treatment; this behavior was accompanied by a normal LLA value. 
The second group (n = 11 patients) showed an initial high value of the TC to 
HDL-C ratio (> 6.9), which was nonresponsive to the diet, and a low LLA value. 
Of particular interest is the third group (n = 9 patients) in which an initial high 
TC to HDL-C ratio (> 6.9) fell to below 6.9 in reaction to the dietary interven-
tion, while the LLA was as higher than in the first mentioned group of patients. 
LPL was not different in these three groups of patients showing different responses 
to dietary intervention. 
The values of the endocrine parameters in relation to the three different 
response patterns are shown in Table VU. No specific major effect on dietary 
lowering of TC could be found for insulin, estradiol-17~. testosterone, cortisol, 
thyroxine, T3-resin uptake and the thyroid stimulating hormone. In the group of 
patients that were responsive to the dietary intervention, triiodothyronine was 
higher than in both other groups. 
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Table VIII shows the average initial coronary score values and the mean changes 
over the study period for the three different lipid lowering response patterns. 
TC 
CHANGE IN HDL·C RATIO 
4.0 
3.0 n = 35 
r ~ - 0.196 
y !.03 • 0.12x 
p = ns 
. 2.0 
+ 3.0 + 2.0 + 1.0 - 1.0 -2.0 + 3.0 -4.0 
CHANGE IN CORONARY SCORE (mm) 
FIGURE 3 
In this _figure the relationship between the change in absolute coronary scores (mm) and the change in 
the ration of total cholesterol (TC) to HDL~C from baseline values is shown. HDL~C = high density 
lipoprotein cholesterol (mmolll). 
Discussion 
Although this study is hampered by the fact that no pre-stndy endocrine and 
postheparin lipoprotein lipase activities were available, the following conclusions 
may be drawn taking into account comparable data from other studies:34 
Firstly, in the presence of advanced coronary atheroclerosis, progression of the 
disease i.e. its natural progressive course, apparently may be halted or even be 
reversed by dietary intervention. 
Secondly, LLA and not LPL is negatively correlated to the degree of progression 
of coronary atherosclerosis, suggesting a key role for the former enzyme. 35 The 
levels of all analyzed hormones, with the exception of T3 and T4 were not different 
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when the no lesion growth group was compared to the progression group. 
With respect to the first conclusion, it should be noticed that although the two 
groups studied were comparable with respect to complaints, age, weight, biochemi-
cal status and lipid profile (except for a initial slightly higher TC-value in the 
TABLE IV 
Insulin, sex hormones and cortisol in the no lesion growth and progression groups of patients. 
Testosterone (nmol/1) 
Estradiol . 17~ (pmolll) 
Cortisol (nmoJJl) 
Insulin (mUn) 
All values: means ± s.d. 
TABLE V 
No lesion growth group 
(n ~ 14) 
23.6 ± 12.0 
118 ± 37 
455 ± 97 
12.4 ± 1.3 
Progression group 
(n ~ 21) 
22.3 ± 10.6 
129 ± 31 
479 ± 138 
13.9 ± 1.9 
Thyroid hormone values in the no lesion growth and progression groups of patients at termination of 
the study. 
T3 (nmolll) 
T, (nmolll) 
T3-resin uptake(%) 
TSH (mU/ml) 
No lesion growth group 
(n ~ 14) 
2.24 ± 0.36 - p < 0.01 -
99 ± 14 - p < 0.01 -
27.3 ± 2.5 
1.9 ± 2.5 
Progression group 
(n ~ 21) 
1.86 ± 0.28 
115 ± 18 
28.0 ± 3.1 
2.4 ± 2.8 
Abbreviations: T3, Triiodothyronine~ T4, Thyroxine: TSH. Thyroid Stimulating Hormone. All values: 
means± s.d. 
TABLE VI 
Dietary lipid lowering effects on the posthcparin lipoprotein lipase activities and on lipid fractions. 
TOHDL ratio 
Initial value > 6.9 > 6.9 ~ 6.9 
Value during study ~ 6.9 > 6.9 ~ 6.9 
Number of patients (n ~ 9) (n ~ 11) (n ~ 15) 
TC/HDL-C 6.20 ± 0.70 
-***- 8.38 ± 1.09 •**- 5.10 ± 0.72 
p < 0.05 
TG 1.21 ± 0.54 •**- 2.46 ± 1.04 •**- 1.13 ± 0.42 
n.s. 
LLA 480 ± 149 
-***- 244 ±104 •**- 426 ±144 
I n.s. 
LPL 85 ± 38 -n.s.- 78 ± 20 -n.s.- 89 ± 23 
n.s. 
Abbreviations: TC. total-cholesterol (mmol/1): HDL-C. high-density-lipoprotein-cholesterol (mmol/1): 
TG. triglycerides (mmol/1): LLA.liver lipase activity (mU/rnl): LPL lipoprotein lipase (mU/rnl): 1 mU 
= mmoles free fatty acids released/min, All values: means ± s.d.; n.s .. not significant. * p < 0.05: 
** p < 0.01: *** p < 0.001. 
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progression group), it cannot be excluded that the two groups of patients differed 
in other parameters. The interpretation of the results from this study is also limited 
to some extent by the lack of a control group. 
However, as has been shown before, coronary atherosclerosis is an almost 
unequivocally progressive disease and therefore any evidence of nonprogression 
may be considered as an indication of a deviation from the natural course of the 
disease. 3637 Difficulties in the quantitative evaluation of atherosclerosis have been 
described elsewhere.38·39 
The purpose of this study was threefold: 
1. To assess the relationship between the diet induced changes in lipid values and 
the progression of coronary atherosclerosis. 
TABLE VII 
Dietary lipid lowering effects and endocrine parameters. 
TOHDL ratio 
Initial value > 6.9 > 6.9 :::; 6.9 
Value during study :s.; 6.9 > 6.9 ~ 6.9 
Number of patients (n = 9) (n = 11) (n = 15) 
In (mU/ml) 11.2 ± 1.4 13.7 ± 2.9 14.3 ± 40 
p < 0.05 
E2 (pmolll) 114 ± 37 120 ± 38 124 ± 4.3 
T (nmolll) 19.6 ± 4.2 18.2 ± 75 19.9 ± 4.3 
C (nmolll) 398 ± 89 480 ± 134 472 ± 121 
T, (nmol) 2.4 ± 0.4 -***- 1.7 ± 0.2 1.9 ± 0.9 
-**-
T, (nmol!l) 90 ± 19 109 ± 24 106 ± 16 
TTresin uptake(%) 26.1 ± 2.6 28.8 ± 2.9 28.1 ± 2.7 
TSH (mU/ml) 2.2 ± 2.4 1.0 ± 2.6 1.8 ± 2.0 
Abbreviations: In. Insulin; E2. Estradiol-1713; T. Testosterone: C. Cortisol; T3• Triiodpthyronine; T4• 
Thyroxine: TSH. Thyroid Stimulating Hormone: All values: means± s.d.; * p < 0.05: ** p < 0.01: 
*** p < 0.001. Other relations were not significantly different. 
TABLE VIII 
Dietary lipid lowering effect and the initial average coronary score and the response pattern changes 
over the study period. 
TOHDL ratio 
Initial value 
Value during study 
Number of patients 
Average initial 
coronary score 
Mean change in mm 
Range of changes 
All values: mean ± s.d. 
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> 6.9 
~ 6.9 
(n = 9) 
> 6.9 
> 6.9 
(n = 11) 
::::; 6.9 
:::::;: 6.9 
(n = 15) 
10.88 ± 1.52 -n.s.- 10.71 ± 1.40 -p < 0.05· 0.64 ± 1.92 
'------p < 0.05----_j 
+ 0.38 - 1.09 + 0.07 
(- 1.09 to+ 2.47) (- 3.10 to+ 0.26) (- 1.25 to + 2.05) 
2. To assess the relationship between the postheparin lipoprotein lipase activities 
and the progression of coronary atherosclerosis on one hand and the diet 
induced lipid value changes on the other hand. 
3. To assess the role of several atherosclerosis related hormones and the progres-
sion of coronary atherosclerosis. 
Concerning the first question, a clear and powerful positive relationship has been 
established between diet (the amount of cholesterol and poly unsaturated fatty 
acids) lipid level changes and the rate of progression of coronary atherosclerosis. 22 
As had been stated before, the postheparin lipoprotein lipase activities are impor-
tant modulators in lipid metabolism determining to a certain degree the ratio 
between HDL and LDL cholesterol. 
To study the possible relationship between LLA and LPL, and the degree of 
change of coronary atherosclerosis in men with advanced atherosclerosis, a lower-
ed LLA and a normal LPL level may be assumed for reasons mentioned before. 34 
This seems valid as the initial coronary atherosclerotic values, expressed in terms of 
coronary scores, were essentially not different (Table II). As may be derived from 
the results, LLA was significantly higher in the no lesion growth group of patients 
but still within the normal range, independently from all other lipoprotein parame-
ters including LPL (Table III). 
The results may suggest a possible threshold value for cholesterol for the 
induction of nonprogression of advanced coronary atherosclerosis; this is based on 
the fact that the decrease in TC level in the progression group was even largerthan 
in the no lesion growth group (Table III). A lowered LLA may impair the 
mobilization of TC from peripheral cells by HDL by hampering with the excretion 
of cholesterol in the liver to be converted to bile acids. Therefore, a lowered LLA 
may contribute to a higher cholesterol pool and as a result contribute to the 
progression of atherosclerosis. 
Although LLA was only measured at the end of the study, results clearly 
demonstrate that those patients that responded to diet with a lowering of the TC 
values, showed no further lesion growth or possibly even regression. This may 
indicate those patients that may benefit from the prescribed diet and those who 
probably do not. In the future a period of only three to six months may be sufficient 
to discriminate those who may profit from diet and those who do not by measuring 
the LLA level, although this obviously requires further study. 
It is of interest to note that those patients with an initial and continuing low TC/ 
HDL-C ratio, had the lowest coronary scores, hence the most extensive atheroscle-
rotic disease (Table VIII). Since they did not appear to be the patients with the 
greatest tendency to regression of the atherosclerotic process, as measured by the 
average change (mm) in coronary scores, other factors besides the lipoproteins and 
lipases, have to be assumed (Table VIII). 
The Leiden Intervention Trial showed that LLA measured following dietary 
intervention is strongly correlated to changes in coronary atherosclerotic lesion size 
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(Figure 2). However, whether a causal relationship may be assumed between LLA 
and the changes observed cannot be concluded from these data. A strong relation-
ship between the changes in TC/HDL-C ratio and those in the coronary scores was 
not observed (Figure 3). 
As far as the third question concerning endocrine parameters, a differentiation 
must be made between the various possibly atherosclerotic growth related hormo-
nes and the progression of coronary atherosclerosis. Diabetes mellites or abnormal 
levels of insulin (relative or absolute) are correlated te acceleration of progression 
of coronary atherosclerosis. 40 Cortisol, the main adrenal cortical stress hormone, is 
also positively re"Iated to the rate of progression of coronary atherosclerosis.41 No 
significant difference between the groups mentioned could be established at the 
end of our study, suggesting that no important role for both of these atherogenic 
hormones exists (Table IV). 
Estradiol-17~ (E2) has been considered to be anti-atherogenic and was even 
administered in pharmacologic doses in the Coronary Drug Project, 42 but was later 
withdrawn for reasons that in those patients receiving estradiol a significantly 
higher percentage suffered a sudden death. Nevertheless, E2 which in men is 
mainly derived from testosterone (T), is known to show a positive correlation to 
the degree of coronary atherosclerosis. 43 Our study showed that after two years of 
dietary intervention no significant difference could be found in E2 and T values 
between the no lesion growth and the progression groups (Table IV). 
Of particular interest is thyroid hormone action in relation to atherosclerosis. 
The TC measurement used to be a marker for the metabolic state. When TC was 
high, a low thyroid function was assumed. 44 Although it is wellknown that in 
hypothyroidism coronary atherosclerosis is severe, a clear advantage from thy-
roxine administration has not been shown to benefit a general population. The 
Coronary Drug Project even withdrew thyroxine administration as a therapeutic 
drug after the establishment of severe side effects in coronary atherosclerosic 
patients.45 
Nevertheless, it is of interest to derive from the results that patients showing no 
lesion growth apparently have a normal although higher metabolic state than the 
progression group patients, as measured by T3 levels (Table V). A possible 
explanation may be that at the end of the study, those patients showing progression 
were using beta blocking agents to a greater degree than the patients from the no 
lesion growth group. As beta blocking agents inhibit the conversion ofT4 to T3, and 
as no significant different number of patients on beta blocking agents existed, the 
different metabolic state of these patients in the no lesion growth group as 
compared to the progression group cannot be explained by the usage of beta 
blockers. 
Finally, it may be concluded from this study, that the levels of insulin, cortisol, 
estradiol, and testosterone with the exception of T3 and T4, were not essentially 
different in the no lesion growth and progression groups, suggesting no major 
atherogenic modulating effects of these before-mentioned hormones. 
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CHAPTER VI 
Progression and Regression of Coronary 
Atherosclerosis. 
The role of lipoproteins, lipases and thyroid 
hormones in coronary lesion growth. 
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University Rotterdam, and the Department of Cardiology4 and the Institute of Social Medicine,5 
University of Leiden_. The Netherlands 
Summary 
Relations between lipoprotein fractions, postheparin lipoprotein lipase activities, 
thyroid hormones and coronary lesion growth were studied among 35 male patients 
with severe cononary atherosclerosis and stable angina pectoris, who had 
participated in the lipid lowering Leiden, Intervention Trial. Coronary arterio-
graphies were performed at the beginning of the study and 2 years later at 
termination. The lesions were quantitated with a computer-based analysis system 
to assess the progression rate of coronary lesions on the basis of the absolute 
arterial dimensions in a patient's coronary tree: for these purposes an absolute 
coronary score was computed. On the basis of the absolute coronary scores, the 
entire group of patients could be divided into a no lesion growth group (14 
patients) and a progression group (21 patients). Lipoprotein fractions, lipoprotein 
lipases and thyroid hormones were determined after two years of intervention. No 
significant difference was found between the no lesion growth or regression and 
progression groups of patients for total-cholesterol (TC) and LDL-cholesterol 
(LDL). The VLDL-cholesterol (VLDL) and the triglycerides (TG) were signifi-
cantly higher (p<0.05) and HDL-cholesterol (HDL-C) was almost significantly 
lower (p<0.10), in the progression group. Lipoprotein lipase (LPL) values 
were not significantly different in the groups with and without lesion growth 
Hepatic lipase (HL) values, however, were significantly higher in the no lesion 
growth group, as compared to the progression group. The biologically active 
thyroid hormone, triiodothyronine (T3) was significantly lower (p<0.01) in the 
progression group as compared with the no lesion growth group. Multivariate 
regression analysis showed HL to be the most important determinant of changes in 
coronary atherosclerosis. T3 and HDL were also independently inversely related to 
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coronary lesion growth. The probably enhanced conversion of thyroxine (T4) to the 
more metabolic active T 3 could imply that the reversed cholesterol transport 
mechanism may take place at a higher rate in the no lesion growth group than in 
the progression group. 
J:ntroduction 
Coronary atherosclerosis resulting in angina pectoris, myocardial infarction or 
sudden death remains a major contributor the epidemic of cardiovascular diseases. 
One of the most important factors that determine the rate of progression of 
coronary atherosclerosis is a disordered lipid metabolism'·' A positive correlation 
has been demonstrated between the morbidity and mortality of coronary heart 
disease and the serum lipid fractions.4-5 Serum levels of certain lipoprotein fractions 
such as the low densiry lipoprotein (LDL), the major carrier of cholesterol, have a 
strong positive correlation to the incidence of coronary atherosclerOtic heart 
disease (CHD). The fraction of the high-density-lipoproteins (HDL) is considered 
'anti-atherogenic' as this fraction is inversely correlated tot development of CHD. 6 
The postheparin lipoprotein lipase activities belong to the class of modulators of 
lipoprotein metabolism affecting the ratio between HDL and LDL-cholesterol.7' 9 
These enzymes, located in endothelial vascular cells are released into the blood-
stream by intravenous heparin administration.7 While lipoprotein lipase (LPL) 
plays a major role in the removal of plasma triglycerides (TG), the role of hepatic 
lipase (HL) is less clear. Both enzymes play a role in HDL-metabolism. It has been 
established that LPL is positively correlated with HDL-cholesterol, 10 while the 
other lipase, HL, is negatively correlated with this fraction 11 As HL may play a 
role in HDL-cholesterol transport to the liver and/or in the metabolism of the 
atherogenic intermediate-density-lipoproteins (IDL), it has been proposed that 
conditions with a low( ered) HL are unfavorable with regard tot atherosclerotic 
conditions. 12·13·33 This knowledge together with the inverse relationship of HL with 
HDL(-cholesterol) implicates that a high HDL-cholesterollevel may not always be 
advantageous. In line with these considerations we found that normolipedemic 
men with angiographically defined coronary atherosclerosis have a lower HL than 
controls without coronary atherosclerosis.14 
Thyroid hormone, more specifically triiodothyronine (T3), is a factor known to 
alter lipid metabolism46• In hypothyroidism, LDL rises and HDL falls. With 
thyroid substitution therapy, a normalization of the lipid disorder ensues. 36 The 
serum level to thyroid hormone is also known to be correlated to the postheparin 
lipoprotein lipases3S and part of the serum lipid level changes may be due to 
changes in the activities of these enzymes. 
Recently the effect of dietary intervention on the development of the atheroge-
nic process was studied in a group of patients with severe coronary atherosclerosis: 
The Leiden Intervention Trial.21 End points for this study were the measurements 
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of the rates of change of arterial dimensions as assessed by coronary arterio-
graphy." Conventional visual interpretation of the severity of arterial lesions by 
coronary angiography is hampered by large inter- and intra-observer variabi-
lity .16-18 To circumvent these problems, in the Lei den trial a quantitative computer 
assisted image processing technique was employed to assess the severity of coro-
nary obstructions from 35 mm cine-angiograms in a highly objective and reproduci-
ble way .19.20 At the final examination of the trial, lipoproteins, LPL, HL and 
thyroid hormones were determined in all 35 male patients. These variables were 
studied in relation to coronary lesion growth during an observation period of two 
years. The results of these analyses are reported here. 
Methods 
Thirty-five male patients with chronic stable angina pectroris were selected to 
participate in a lipid lowering dietary intervention program (The Leiden Interven-
tion Trial). At the end of the two-year intervention period - the study lasted from 
1978 tot 1982- a repeat coronary arteriography was performed. 
The intervention consisted of a vegetarian diet with a polyunsaturated to 
saturated fatty acids (P/S) ratio of 2 and with a total fat content of 34 energy 
percent. It contained 100 mg cholesterol per day or less and was low caloric, if 
appropriate. 
Serum total-cholesterol (TC) and HDL-cholesterol (HDL-C) were determined 
according to Abell's method;22 HDL-C was isolated by precipitating other lipopro-
teins with magnesiumphosphotungstate and cholesterol was determined in the 
supernatant."' Triglycerides (TG) were measured at the end of the study, after an 
overnight fast in a basal resting state.24 The cholesterol concentration in the VLDL 
lipoproteins was calculated according to Friedewald et al37 by dividing serum 
triglycerides by 5. LDL-cholesterol was calculated by subtracting HDL- and 
VLDL-cholesterol from total cholesterol. Postheparin lipoprotein lipase activities 
were measured as follows: thirty minutes after introduction of an intravenous 
catheter in the right brachial vein heparin (50 IU/kg bodyweight, Thromboliquine, 
Organon, Oss) was administered intravenously. Blood was collected from the left 
brachial vein in disodium EDTA (2.7 mmol/1) on ice twenty minutes after the 
administration of heparin. Blood was centrifuged at 4 oc for 30 minutes at 3000 
r.p.m. and plasma was stored at -20°C. LPL, HL were measured as described by 
Huttunen et al.25 
All biochemical parameters were measured at the final examination. 
Coronary arteriography 
The coronary angiography procedure was performed with the Judkins techni-
que26 The initial and sequential coronary arteriographies were performed by the 
same angiographer. At the second arteriography special care was taken to obtain 
projections identical to those of the first angiography. 
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Computer processing of coronary angiograms 
Quantitative analysis of coronary arterial segments was carried out with the 
computer-based Cardiovascular Angiography Analysis System (CAAS); details of 
the analysis procedure and the results of a validation study have been described 
elsewhere20•27 The system allows the accurate delineation of the contours of user-
selected coronary arterial segments by means of automated edge-detection algo-
rithms. An example of the quantitative analyses of the pre- and post-intervention 
coronary angiograms of one particular coronary segment is shown in Figure 1. 
Diameter values are expressed in absolute terms (mm) by using the intracardiac 
catheter as a scaling device. The severity of a coronary obstruction was expressed 
as a percentage diameter reduction with respect to a user-defined reference 
position proximal or distal to the stenosis and by means of the absolute value of the 
diameter at the site of maximal obstructions. For arterial segments showing no 
focal obstruction, the mean diameter value over a user-defined length was com-
puted. 
Cineframes to be analysed were selected as closely as possible to the enddiastolic 
phase. When a praticular segment of a coronary artery overlapped with another 
vessel, a cineframe was selected at another instant in time. 
The variablility of repeated analysis of cine-angiograms in terms of absloute 
arterial dimensions of the CAAS system has been found to be less than 0.11 mm 
and in terms of percentage coronary arterial narrowing for coronary obstructions 
less than 2.74% 20 A total of nine major coronary segments were assessed accor-
ding to the recommendations by the American Heart Association (right coronary 
artery, RCA: proximal, mid and distal portions; left anterior descending artery, 
LAD: proximal, mid and distal portions; left circumflex artery, LCX: proximal and 
distal protions; and the main stem, main). These nine coronary artery segments 
were analyzed in at least two, preferably orthogonal projections. For each analyzed 
coronary segment the severity of an obstruction, if present, was computed in terms 
of relative and absolute measurements, as well as the mean diameter over one or 
more nonobstructed portions of this segment. The absolute size of an obstruction 
was computed as the mean diametervalue of the obstruction diameters assessed in 
the different views. The absolute coronary score was determined as follows: for 
each of the four large coronary arteries (RCA, main, LAD, LCX) the mean 
vascular diameter at the different sites of the obstructions as assessed from the 
available views was computed in mm. If no obstruction in a coronary artery was 
present, the mean value of the computed average diameter measurements for the 
different segments of this artery was subsitituted. Adding these 4 mean diameter 
values resulted in the absolute coronary score. The changes in absolute coronary 
scores over the two year diet period were simply determined as the differences in 
the pre- an postdiet scores. 
A patient was considered to have a progressive disease, if the absolute coronary 
score showed a decrease. No lesion growth or regression of the disease was 
assumed if the coronary score showed an increase. 
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F1GURE 1 
Example of quantitavive results of one particular coronary segment (proximal part of right coronary 
artery) in the pre- (above) and post- (below) study situation. In this particular case of a proximal 
segment of a right coronary artery the luminal obstruction diameter decreased from 3.18 mm to 3.08 
mm. Due to the fact that the reference diameter showed a larger decrease in size than the obstruction 
diameter, the percentage diameter stenosis decreased as well from 40% to 31%. 
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Statistical methods 
Means were compared by the two sample Student's t-test (two-sided). Relations 
between continuous variables were analyzed by linear regression analysis. The 
number of possible determinants of coronary lesion growth was reduced by using a 
backward elimination program. 29 Independent variables remained in the regression 
equation when their p-value was lower than 0.10. 
Results 
Twenty-one of the 35 patients showed progression of coronary atherosclerosis and 
14 patients showed no lesion growth or even regression (Table I). No significant 
difference was found between the progression and no lesion growth group with 
respect to their initial coronary lesion scores. Furthermore, significant differences 
were not found for weight, age, blood pressure and smoking habits. Persistence of 
anginal complaints at the end of the trial was, however, significantly (p < 0.01) 
higher in the progression group (Table I). 
Table II shows the lipoprotein fractions, the lipoprotein lipases and the thyroid 
hormones at the termination of the study. LDL cholesterol levels were similar in 
both groups, but VLDL cholesterol was significantly higher among the men who 
showed progression. HDL cholesterol was lower among the men who showed 
progression compared to the men without progression. This difference was almost 
statistically significant (p < 0.10). HL was significantly higher (p<0.001) in the no 
lesion growth group while LPL was not different in the two groups. The mean HL 
levels were also significantly lower than normal. No significant correlations could 
be found between HL and HDL-C, VLDL-C and LDL-C values. Of the thyroid 
hormones, T 3 was significantly higher and T4 was significantly lower in the no lesion 
growth group. Both parameters remained within the normal range. T,-resin uptake 
dit not differ between the two groups. 
After univariate analysis, multiple lineair regression analysis was performed 
using coronary lesion growth as dependent and lipoprotein fractions, hepatic lipase 
and thyroid hormones as independent variables. Hepatic lipase, T3 and HDL-
cholesterol were independently significantly inversely related to coronary lesion 
growth (Tabel HI). 
Discussion 
At termination of the study, lipoprotein fractions (TC, TG and HDL-C), lipopro-
tein lipases (LPL and HL) and thyroid hormones (T; and T4) were measured, as 
these parameters may be related to progression of atherosclerosis. 5·14·21.39-"". 
In our study, calculated LDL-cholesterol, the main component of TC, was not 
significantly different in the progression and the no lesion growth groups. This 
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TABLE l 
Clinical data and coronary scores in patients showing no lesion growth or progression of coronary 
atherosclerosis at termination of the study. 
Age (years)* 
Number of patients: 
Smoking 
Angina pectoris 
Syst. BP (mmHg) 
Diast. BP (mmHg) 
Quetelet index (kg/mz) 
cs• (mm) 
,;cs• (mm) 
n = number of patients 
CS = coronary score (mm) 
no lesion growth group 
(n ~ 14) 
49.8 ± 8.0 
poststudy 
6 (42%) 
6 (42%) 
124 
80 
23.9 
11.14 ± 1.79 
+1.02 ± 0.69 
progression group 
(n ~ 21) 
52.4 ± 7.8 
poststudy 
5 (23% 
17 (80%) 
128 
85 
23.4 
9.17 ± 2.12 
-1.20 ± 0.96 
b.CS = the difference (mm) in absolute coronary scores form the pre- and post-study angiograms 
mean± S.D., otherwise mean values 
seems to be in contrast to previous findings where TC is an important risk factor for 
coronary artery disease. 39 However, in the prospective analysis of the Lei den 
Intervention Trial, the TC level was significantly related to occurrence of progres-
sion of atherosclerosis. 
The fact that no significant difference was found in our study for LDL-
cholesterol between the two groups is in agreement with Vlietstra et al40 and 
Jenkins et al. 41 However, one has to take into account that these patients had been 
on an intervention diet for two years. 11 The variation between patients may 
therefore be reduced. This may be an explanation for observing no relation 
between the calculated LDL at termination of the trial and coronary lesion growth. 
However LDL values were higher at termination of the trial in the no lesion growth 
group when compared with the progression group. These results suggest that 
reversed cholesterol transport is enhanced in the no lesion growth group. Hypothy-
roidism is known to be associated with elevated TC values and TC normaliza-
tion36 follows thyroid hormone substitution therapy. Patients who died with clinical 
symptoms of hypothyroidism had significantly more extensive coronary atheros-
clerosis than controls.43 Thyroxine (T4), quantitatively the main secreted thyroid 
hormone, is converted to the metabolically active T3 in the peripheral tissues. 44 In 
our study T3 was significantly higher and T4 significantly lower in the no lesion 
growth group, implying a higher metabolic state. Beta blocking agents intervene 
with the conversion of T4 tot T3 .45 No significant difference was found in the use of 
these agents in the two groups studied: eleven out of fourteen in the no lesion 
growth group and twelve out of twenty-one in the progression group. 
The post-heparin lipoprotein lipases, LPL and HL, are important modulators of 
the lipid metabolism7 .10 The extent of coronary atherosclerosis has been shown to 
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TABLE II 
Lipids. lipoproteins. lipoprotein lipases and thyroid hormones values at the final examination of the 
Leiden Intervention Trial in patients showing no lesion growth or progression of coronary atheroscle-
rosis. 
no lesion growth group progression group 
n = 14 n = 21 
TC 233 ± 52 254 ± 76 
TG 97 ± 74 162 ± 86' 
HDL-C 39 ± 7 37 ± 4 
LDL-C 162 ± 44 188 ± 76 
VLDL-C 21 ± 16 36 ± 19' 
LPL 86 ± 36 87 ± 34 
HL 499 ± 146 298 ± 190**"' 
T, 2.24 ± 0.36 1.68 ± 0.28** 
T, 99 ± 14 115 ± 18'"* 
T3-resin uptake 
TC 
TG 
LDL-C 
HDL-C 
VLDL-C 
HL 
LPL 
27.3 ± 2.5 
total-cholesterol (mg/dl) 
triglycerides (mg/dl) 
low-density-lipoproteins (mg/d.I) 
high-density-lipoprotein cholesterol (mg/dl) 
very low density lipoprotein-cholesterol (mg/dl) 
hepatic lipase (mU/ml) (normal values 472 ± 127) 
lipoprotein lipase (mU/ml) (normal values 87 ± 32) 
p < 0.05 
p < 0.01 
p < 0.001 
T3 triiodothyronine (ngll) 
T~ thyroxine (ngll) 
TTresin uptake(%) 
n = number of patients. all values are mean ± s.d. 
1 mU = mmoles fatty acids releasedJmin. 
TABLE III 
28.0 ± 3.1 
Univariate and multivariate standardized regression coefficients for HDL cholesterol. hepatic lipase 
and T3 in coronary lesion growth. 
HDL-cholesterol (mg/dl) 
Hepatic lipase (mU/ml) 
Triiodothyronine (T3) (ng/1) 
.. 
... 
R' 
p < 0.05 
p < 0.01 
p < 0.001 
univariate analysis 
multivariate analysis 
uv 
-0.30 
-0.55*** 
-0.48** 
standardized 
regression coefficients 
MY 
-0.30' 
-0.47** 
-0.33* 
0.51 
uv 
MY 
R' proportion of explained variance in the dependent variable. 
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be inversely correlated to the HL level. 14 On the other hand HL and LPL have also 
been shown to be correlated to thyroid hormone levels.46 In our study HL was 
significantly higher in the no lesion growth (or regression) group as compared to 
the progression group. Multivariate analysis indicated that HL was the most 
powerful predicting parameter with regards to regression of angiographically 
defined coronary atherosclerosis (Table HI). Next to HL, T3 and HDL-C were also 
important in predicting regression of atherosclerosis. All these parameters were 
independent contributors to the process, defined as regression of coronary atheros-
clerosis and explained more than 50% (Table HI), in the variance of lesion growth. 
This means that T3 not only influences the atherosclerotic regression proces by 
virtue of its possible stimulating effect on HL but the fact that HL is the most 
powerful predictor points to an important role of HL in the cholesterol tr;msport 
mechanism. 33 
What the exact role of HL in lipoprotein metabolism is, remains yet to be 
clarified. This enzyme has been suggested to play a role in the uptake of cholesterol 
from HDL by the liver.33 There are indications that this lipase may play a role in 
the conversion of IDL to LDL.32 A lowered HL would thus either lead to an 
impaired cholesterol removal by the liver and reverse cholesterol transport mecha-
nism, and/or to an accumulation of the highly atherogenic IDL, leading to 
atherogenic conditions. 13 
References 
1 LIPIDS RESEARCH CLINICS PROGRAM:. The Lipid Research Clinics Coronary Primary Prevention Trial 
Results. I Reduction in incidence of coronary heart disease. lAMA 1984, 251. 351~364. LIPIDS 
RESEARCH cumcs PROGRAM. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II 
The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 
1984. 251. 365-374. 
2 CONSENsus CONFERENCE. Lowering Blood Cholesterol to Prevent Heart Disease. JAMA 1985. 253. 
2080-2086. 
3 LEVY R.I. Cholesterol and disease- what are the facts? JAMA 1982, 248, 2888-2890. 
4 GLUECK c.r. Relationship of lipid disorders to coronary heart disease. AmJ Med 1983.74 (SupplSA). 
10-14. 
5 LEvY R.I. Cholesterol, lipoproteins, apoproteins and heart disease: present status and future prospects. 
Clio Chern 1981. 27. 653-662. 
6 BARR. D.P .• RUSS. E.M •• EDER H.A. Protein-lipid relationships in human plasma. Am J Med 1985. U, 
480-493. 
7 NILSSON-EHLE. P •• GARFINKEL, A.S., SCHOTZ. M.C. Lipolytic enzymes and plasma lipoprot'ein metabolism. 
Ann Rev. Biochem 1980.49. 667-693. 
8 JANSEN, H •• HDLSMANN, w.c. Heparin-relesable (liver) lipase(s) may play a role in the uptake of 
cholesterol by steroid-secreting tissues. Trends Biochemical Sciences 1980. 265-268. 
9 NIKKI:r..A. E.A. Metabolic regulation of plasma high density lipoprotein concentration. Eur J Clin Invest 
1978. 8. 110-113. 
10 KEKKI, M. Lipoprotein lipase action determining plasma high-density lipoprotein cholesterol level in 
adult normolipaemics. Atherosclerosis 1980.37. 143-150. 
11 JANSEN. H .• VANTOL, A •• HDLSMANN, w.c. On the-metabolic function of heparin releasable liver lipase. 
Biochem Biophys Res Commun 1980. 92, 53-59. 
12 SCHONFELD. G. Disorders of lipid transport-Update 1983. Prog Cardiovasc Dis 1983. 26. 89-108. 
75 
13 HDLSMANN. w.c .• JANSEN, H. High myocardial and low hepatic lipoprotein lipase activities responsible 
for the initiation of atherosclerosis. Biochem Mcd 1975, 13. 293-295. 
14 BARTH. J.D •• JANSEN. H •• HUGENHOLTZ. P.G .• B!RK:ENHAGER. J.C. Post-heparin lipases_. lipids and related 
hormones in men undergoing coronary arteriography to assess atherosclerosis. Atherosclerosis 1983, 
48. 235-241. 
15 BROWN. B.G. BOLSON. E.L .• DODGE. H.T. Arteriographicassessmentofcoronary atherosclerosis: Review 
of current methods, their limitations and clinical applications. Arteriosclerosis 1982. 2. 2-15. 
16 ZIR. L.M .• MILLER. S.W .• DINSMORE, R.E .• GILBERT, J •• HARTIIORNE. J.W. [nterobserver variablility in 
coronary angiography. Circulation 1976. 53. 627-632. 
17 DEROUEN. T.A .• MURRAY. LA .• OWEN. w. Variability in analysis of coronary arteriograms. Circulation 
1977. 55. 324-328. 
18 DETRE. K.M., WRIGHT. E .• MURPHY. M.L. Observer agreement in evaluating coronary angiograms. 
Circulation 1975. 52. 979-986. 
19 CHANDLER. A.B .• BOND. M.G .• INSULL. J. w. ET AL. Quantitative evaluation of atherosclerosis. Arterioscle-
rosis 1983. 3. 183-186. 
20 REIBER. J.H.C •• SERRUYS. P.W •• KOOIJMAN. C.J. ET AL. Assessment of short-, medium- and long-term 
variations in arterial dimensions from computer-assisted quantitation of coronary cine-angiograms. 
Circulation 1985. 71. 280-288. 
21 ARNTZENIUS. A. C .• KROMHOUT. D .• BARTH, J.D. ET AL. Diet.. Lipoproteins and the progression of coronary 
atherosclerosis. The Leiden Intervention Trial. N Engl J Med. 1985. 312. 805-811. 
22 ABELL. A.A., LEVY. B.B •• BRODIE. B.B •• KENDALL. F.E. A simplified method for the estimation of total 
cholesterol in serum and demonstration of irs specificity. J. Biol. Chern. 1952, 195. 357-366. 
23 LOPES-VIREI.LA. M.F._ STONE, P •• ELLIS, S., COL\VELL,J .A. Cholesterol determination inHDL-lipoproteins 
separated by their diffent methods. Clin. Chern. 1977. 23. 882-384. 
24 WAHLEFELD. A.W. Triglycerides determination after enzymatic hydrolysis. In: H.U. Bergmayer. ed. 
Methods in enzymatic analysis vol. D. Academic Press New York N.Y .. 1974. 1831. 
25 HUITUNEN. J.K •• EHNHOLM. C., KINNUNEN, P.K .• NIKKII.A.. E.A. An immunochemical method for the 
selective measurement of two triglyceride lipases in human postheparin plasma. Clin. Chern. Acta 
1975. 63. 335-347. 
26 JUDKINS. M.P. Selective coronary arteriography I. A percutaneous transfemoral technique. Radiology 
1967. 89, 815-824. 
27 REIBER. J.H.c .• KOOUMAN. c.J •• SLAGER. c.J .• ET AL. Coronary artery dimensions from cineangiograrns-
methodology and validation of a computer-assisted analysis procedure. IEEE Trans Med. Imaging 
1984. MI-3. 131-141. 
28 LEAMAN. D.M., BROWER. R.W •• MEESTER. G.T •• SERRUYS. P.W .• VAN DEN BRAND, M. Coronary artery 
atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular 
function. Circulation 1981. 63, 285-292. 
29 sPSs-x USERS GUIDE. SSPS Inc. Cliicago. New York. Toronto. Me. Graw-HilL Book Company.1983. 
30 BRUSCHKE. A. V .G .• WYERS. TH.S. KOLSTERS. W .• LANDMAN. J. The anatomic evolution of coronary artery 
disease demonstrated by coronary arteriography in 256 nonoperated patients. Circulation 1981. 63. 
527-536. 
31 PROUDffi. W.L •• BRUSCHKE. A.V.G •• SONES, F.M .• JR. Natural history of obstructive Coronary artery 
disease, ten years study of 601 nonsurgical cases. Prog. Cardiovasc. Dis. 1978. 21. 53-78. 
32 HAVEL. R.J. Role of the liver in Atherosclerosis. Arteriosclerosis 1985. 5. 569-580. 
33 JANSEN. H •• HDLSMANN. w.c. Enzymology and physiological role of hepatic lipase. Biochern. Soc. 
Trans 1985. 5. 14-16. 
34 VISSER. T.J •• VANDER HOUT-GOEMAAT. N.L .• DOCI"ER. R. ET AL. Radio-immuno-assay of thyroxine in 
unextracted serums. Neth. J. Med. 1975.18.111-115. 
35 DOCTOR. R .• HENNEMAN. G .• BERNARD. H.F. A radio-immuno-assay for measurement ofT3 in serum. Isr. 
J. Med. Sci. 1972. 8. 1870-1872. 
36 STAMLER. r •• BEST. M.M •• TURNER. J.D. The status of hormonal therapy for the primary and secondary 
prevention of atherosclerotic coronary heart disease. Progr. Card.iovasc. Dis. 1963. 6. 220-235. 
37 fRIEDEWALD. W.T •• LEVY. R.I .• FREDERlCKSON. D.S. Estimation of the concentration of /ow-density 
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clio. Chern. 1972. 18. 
449-502. 
76 
38 ROSSNER, s .. ROSENQVIST. u. Serum lipoproteins and the intravenous fat tolerance test in hypothyroid 
patients before and during substitution therapy. Atherosclerosis 1974. 20. 365-381. 
39 KANNEL. w .B •• MCGEE. D., GORDON, T. A general cardiovascular risk profile. The Framingham Study. 
Am. J. Cardiol. 1976. 38. 46-51. 
40 VLIETSTRA. R.E .• KRONMAL. R.A .• FRYE, R.E •• ET AL. Factors affecting the extent and severity of coronary 
artery disease in patients enrolled in the Coronary Artery Surgery Study. Arteriosclerosis 1982. 2, 208-
215. 
41 JENKINS. P.J .• HARPER. R.w .• NESTEL, P.J. Severity of coronary atherosclerosis related to lipoprotein 
concentration. Br. Med. J. 1978. 2. 388-391. 
42 GORDON. T.,CASTELU, W.P •• HJORTL\..>'ID.M.C .• KANNEL. W.B .• DAWBER, T.R. High-densityfipoproteinasa 
protective factor against coronary heart disease: The Framingham Study. Am. J. Med. 1977. 62.707-
714. , 
43 VANHAELST. L.. NEVE. P .• CHAILLY. P .• BASTENIE. P.A. COronary artery disease in hypothyroidism. 
Observations in clinical myxoedema. Lancet 1967. ii. 800-802. 
44 SCHIMMEL. M .• UTIGER. R.D. Thyroidal and peripheral production of thyroid hormones. Review of recent 
findings and ther clinical implications. Ann. Intern. Med. 1977. 87. 760-768. 
45 WIERSINGA. w .M .• TOUBER, J .L. The influence of bi!ta-adrenoceptor blocking agents on plasma thyroxine 
and triiodothyronine. J_ Clin. Endocrinol Metab. 1977:45. 293-298. 
46 BERTHEZENE, F •• PERROT. L .• DEPARSCAU, L. VALENTIN, C .• RICHARD, L. Hormones thyroi"diennes et 
mitabolisme des lipoprotiines. Ann. d'Endocrin (Paris) 1983. 44. 73-76. 
Submission manuscript for the semi-fmalist participation of the Young Investigator's Award of the X 
World Congress of Cardiology. Washingron D.C.. September 14-19, 1986. 
77 
CHAPTER VII 
Clinical significance of progression and regression 
of coronary atherosclerotic lesions 
The Leiden Intervention Trial 
Jacques D. Barth, M.D. ,1 Alexander C. Arntzenius, M.D., 2 Daan Kromhout, 
Ph.D.,3 Johan H. C. Reiber, Ph.D.4 
1 Department of Cardiology. St. Radboud University Hospital_. University ofNijmegen_. The Netherlands. 
2 Department of Cardiology_. University of Leiden. The Netherlands. 3 Institute of Social Medicine, 
University of Leiden, The Netherlands. 4 Thoraxcenter_. Erasmus UniversitY.. Rotterdam, The Netherlands. 
Summary 
The clinical significance of progression and regression of coronary atherosclerosis 
was studied in the Leiden Intervention Trial. Quantitative measurements of 
coronary arterial dimensions assessed at the beginning of the study with a compu-
ter-based analysis system and after a dietary intervention period of 2 years were 
performed. Progression of lesions occurred in 21 out of the 39 patients, 11 patients 
remained stable, while 7 patients showed clear signs of regression. The effect of the 
intervention diet was stronger on the severe coronary lesions (> 50%) than on 
lesser ones (p < 0.02). ECG as a parameter of coronary atherosclerosis was 
coded according to the Cardiac Infarction Injury Score (CIIS). The CHS score was 
sigoificantly (p < 0.05) correlated with coronary atherosclerosis both before and 
after two years of intervention. 
Persistent exertional angina pectoris at the end of the study was significantly 
(p < 0.01) correlated with progression of coronary atherosclerosis. Vital status, 
3.5 years after final examination was also significantly (p = 0.05) correlated with 
progression of coronary atherosclerosis. We infer from these findings that progres-
sion and regression of coronary atherosclerosis as measured over a period of two 
years, have important clinical implications for the individual patient. 
Introduction 
There is evidence that under certain circumstances the luminal diameters of 
stenotic, presumably atherosclerotic arteries may widen over the years. The 
underlining process - distinct from release of spasm- has been named 'regression 
of atherosclerosis'. When we try to relate regression to our understanding of the 
pathogenesis of atherosclerosis fundamental questions are encountered, as Mali-
now has pointed out:1.2 What is the anatomical substrate for the phenomena? Are 
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certain lesions more likely to regress than others? What variables define regression 
in different circumstances? Does regression (arrest or progression) influence the 
clinical course in patients with cardiovascular arterial disease? 
When one wants to try and find answers to these questions a number of problems 
are encountered. The most serious disadvantage of present day investigation 
techniques is that for the documentation of the evolution of coronary atherosclero-
tic narrowing, serial angiography is required, which almost rules out the possibility 
to observe pro- and regression of atherosclerotic lesions in symptom-free persons. 
A second important problem is caused by the fact that with angiographic films we 
cannot as yet study the tissue surrounding the arterial lumen. Diagnosis of 
regression of atherosclerosis can thus be inferential only. A third obstacle or rather 
group of obstacles concerns the methodology of quantitation of lesions in repeat 
angiography, which is foremost, as stipulated by Blankenhorn et a!. 3.4 For example, 
great care should be taken in obtaining the same angiographic projections at the 
time of the sequential angiographies. Completeness of filling by contrast material 
in the vessel and timing in relation to the cardiac cycle as well as vascular tone are 
yet another group of important factors which should be taken seriously into 
account. Quantitation of changes in diameters has been essentially improved by the 
development of computerized edge-detection techniques. 5·' So far, three serial 
prospective angiographic studies with computer-supported analysis on the possible 
occurence of regression have been published. 6•8•9 In two of these femoral arteries 
were studied and in the third one coronary arteries: The Leiden Intervention Trial. 
Reversibility of atherosclerosis is important for the prevention of clinical seque-
lae of coronary atherosclerosis. The purpose of the present study was to relate pro-
and regression of coronary atherosclerotic lesions to symptoms and signs of the 
disease e.g. ECG-findings, angina pectoris and mortality. 
Patients and methods 
The Leiden Intervention Trial protocol and findings have already been published 
in detail.9 In brief, the relations between diet, serum lipoproteins and the progres-
sion of coronary lesions were studied in 39 patients with stable angine pectoris in 
whom coronary arteriography at the time before the intervention had demonstrat-
ed single or multiple vessel disease with at least one obstruction with a greater than 
50% diameter narrowing. Intervention consisted of the use of a vegetarian diet for 
two years. The diet had a ratio of polyunsaturated to saturated fatty acids of 2 and 
furnished a dietary cholesterol intake of less than 100 mg per day. 
Computer-assisted analysis of the coronary cine-angiograms was carried out with 
the Cardiovascular Angiography Analysis System (CAAS, Thoraxcenter, Rotter-
dam, The Netherlands,'). This system permits the accurate delineation of the 
contours of user-selected coronary arterial segments by means of automated edge-
detection algorithms. The reproducibility of the analyses has been shown to be 
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excellent.7 This reproducibility was assessed on the basis of end-diastolic cinefra-
mes of 13 routine coronary angiograms which were analyzed twice by one techni-
cian with a median interval of 28 days between analyses. The average difference 
between duplicate measurements was found to be negligible ( < 0.001 mm); the 
variability, defined as the standard deviation of the differences between repeated 
measurements, was found to be 0.10 mm.5 
Electrocardiograms (ECG) of the patients at rest were interpreted according to 
the Cardiac Infarction Injury Score (CIIS). 10 The CIIS is a multivariate decision-
theoretic electrocardiogram classification scheme. It uses 11 discrete and 4 continu-
ously measured ECG variables and is based on the use of the standard 12-leads 
ECG. Each feature contributes to the total score according to its weight for 
specified ranges of feature values. The weight coefficient of a continuous feature is 
multiplied by its measured value and the product is added to (or subtracted from) 
the score. The higher the final score, the higher the chance of cardiac injury; the 
scale ranges fran -20 to +80. In the Leiden Intervention Trial electrocardiograms 
were recorded and coded prior to intervention and twelve times during the two 
years of intervention. 
Persistend exertional angina was analyzed by a routine questioning method. 
The vital status of all patients was verified on April 1, 1985. For all patients the 
follow-up period after the final angiogram amounted to at least 3.5 years. 
Statistical methods 
Differences between groups were evaluated by Student's !-test when the depen-
dent variable was continous and the independent variable was categorical. When 
both the dependent and independent variables were categorical, the x' test was 
used. The relation between progression of coronary sclerosis and vital status was 
analyzed by Wilcoxon test. All statistical analyses were carried out with the SPSS-
X statistical package21 
Results 
According to the computer assessment of the pre-intervention cinefilms, a total of 
166 lesions were detected in the 9 major epicardial coronary segments of the 39 
patients. On average, each patient had 4.26 ± 1.52 lesions. Seven patients had 
one-vessel disease, 11 two-vessel disease and 21 patients had three-vessel disease. 
The mean ± s.d. of the minimal diameter of the vessels at the 166 sites of 
obstruction was 2.12 ± 0.99 mm in the first arteriogram and 1.99 ± 1.01 mm in 
the second, illustrating that on average, the coronary lesions of the 39 patients, 
progressed during the two years of obstruction (p < 0.01) (Table I). 
Progression of coronary atherosclerosis was defined as a decrease of 0.1 mm or 
more in the mean coronary diameter (computer assessment). Regression oflesions 
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was defined as a mean increase of 0.2 mm or more, which is two times the standard 
deviation of the difference between repeat measurements. This definition was 
chosen to be certain that in regression an important deviation from the natural 
progressive course had happened. Therefore, in progression only one standard 
deviation was considered snfficient. 
TABLE I 
Number of segments that showed progression, regression or remained stable, when the two sequential 
mean diameter values were compared after two years of intervention. 
Segments studied progression stable regression total 
(Number of segments) 
RCA proximal 21 1 9 31 
mid 14 0 11 25 
distal 6 4 9 19 
Total RCA lesions - 41 5 29 75 
main stem 1 1 1 3 
LAD proximal 15 0 9 24 
mid 8 0 11 19 
distal 5 0 2 7 
Total LAD lesions 28 0 22 50 
LCX proximal 9 2 6 17 
distal 11 5 2 15 
Total LCX lesions 20 7 8 35 
Grand total 90 13 60 163 
Lesions with suspected recanalisation 3 
Total lesions 166 
RCA = Right Coronary Artery 
LAD = Left Arterial Descending coronary artery 
LCX = Left Circumflex Artery 
Using the above criteria, progression of coronary lesion growth occured in 21 out 
of the 39 patients and regression in 7 patients. In 11 out of the 39 patients neither 
progression nor regression was seen to occur, a situation which we called 'stable' 
(Figure 1). Only in 9 patients all lesions progressed, in all other patients both 
progression and regression of lesions were seen to occur in the same individual 
coronary tree. 
Association between computer-assessed dimensions of coronary obstructions for 
each patient and the CIIS score of the ECG, both at onset and at final examination, 
proved to be significant (r = 0.33, p = 0.04 and r = 0.38, p = 0.02 
respectively). 
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FIGURE 1 
Total-cholesterol to HDL-choiesterol ratio mean value between (0) and (2) years as related to the 
computer assessed coronary lesion growth. 
After 24 months of dietary intervention 23 out of the 39 patients still had typical 
angina pectoris on exertion. When these findings were related to the computer-
assessed coronary changes over the two years period, it was concluded that 
persistent angina pectoris was present in 17 of the 21 patients with progression of 
disease, in 5 out of 11 patients with stable lesions and in 1 out of 7 patients with 
regression. Statistical analysis showed that persistent angina pectoris was signifi-
cantly correlated with progression of coronary lesions (Table II). 
The inquiry showed that 5 patients had died and 34 were alive 3.5 years after the 
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final examination (Figure 1). The five deaths all had occured in the group of 21 
patients with progression of disease. The mean change of the coronary obstruction 
diameters in the 5 patients over the 2 years period was + 0.35 mm, thus showing 
considerable progression. The mean change in coronary obstructions of the 
remaining 34 patients still alive, was found to be + 0.09 mm (p = 0.05). 
TABEL II 
Relation between computer assessed changes in coronary diameters and exertional angina pectoris. 
Mean change (mm) 
in obstruction size 
Angina after study 
n = number of patients 
Discussion 
Progression 
n = 21 
+ 0.35 
17 
Stable 
n = 11 
-0.08 
5 
Regression 
n=7 
-0.29 
1 (p ~ 0.005) 
Seven prospective angiographic studies have shown serum lipid levels to be 
associated with atherosclerotic lesion growth. 3·8·9·11·14 In the Leiden Intervention 
Trial for instance, coronary lesion growth correlated significantly with the total-
cholesterol/HDL-cholesterol ratio (r=0.50, p=0.001).9 Disease progression was 
significant in patients who had values for total!HDL-cholesterol that were higher 
than the median (>6.9) throughout the trial period. No coronary lesion growth 
was observed in patients who had lower values for total/HDL-cholesterol than the 
median (""6.9) throughout the trial or who initially had higher values that were 
significantly lowered by dietary intervention. 
It is also important, however, to examine whether the slight changes, that did 
take place in the coronary diameters at the sites of the stenotic lesions have had 
clinical significance for the individual patient. For this purpose we have analyzed 
the electrocardiograms of the 39 patients, the persisting exertional angina pectoris 
and the vital status of the participants 3.5 years after the intervention period. 
The diagnosis of coronary heart disease from electrocardiographic findings has 
been a clinical problem of long standing. To derive reliable information on the 
severity of coronary atherosclerotic lesions from ECG' s at rest is even more 
difficult. Yet, each clinical cardiologist values the 12-leads ECG when assessing the 
patient with angina. Little has been published, however, on the relationship 
between ECG and coronary angiographic findings. Flaming et al, 15 in a multivari-
ate analysis of angiographic, histologic and ECG data, found that ECG abnormali-
ties were more related to the state of the myocardium (fibrosis, etc.) than to the 
stenotic lesions. However, Rautaharju et al, 10 the orginator of the CIIS coding, 
found his scoring system to be considerably more accurate for the diagnosis of 
coronary heart disease than the conventional ECG classifications. Bart et al16 
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compared the ens code findings to the Minnesota Code with the use of a data set 
of 542 ECG's of which 244 were derived from patients with proven myocardial 
illfarction, Results showed that indeed the diagnostic accuracy of ens was greater 
than that of the Minnesota Code, In the Leiden Intervention Trial, as reported 
here, the ens scoring of the 39 patients both at the onset of the study and at the 
final examination correlated significantly, although not strongly, to the computer-
assessed coronary lesions, satisfies the clinical notion that electrocardiograms of 
anginal patients have some bearing on the severity of the disease, 
The presumed association between angina pectoris and coronary stenotic lesions 
has been considered of great importance, but angina pectoris is not a disease but a 
symptom, Therefore, it is of importance to understand and derive from the 
symptom the underlying disease, 
In the Leiden Intervention Trial all 39 patients had angina pectoris when they 
enrolled in the study; and angiographic assessment had shown in each of them an 
atherosclerotic diameter obstruction of 50% or more, None of the patients had 
other heart abnormalities as valvular disease, hypertrophic cardiomyopathies or 
pericarditis, Therefore, it seems perfectly valid to presume that the angina pectoris 
of which the 39 patients suffered could be attributed to their coronary atherosclero-
tic lesions, It seems also fair, but indeed not proven, that any changes in the 
intensity of the anginal symptoms will be derived from changes in the coronary 
atherosclerotic lesions, 17 Most cardiologists have the above presumed association 
in their mind when they take the anatomic changes that they see on the angiograms 
as the principle yardstick in their clinical judgement of patients with angina 
pectoris, 18 It is true that other factors than the degree of narrowing of the coronary 
lumen can be of importance, e,g, the presence of collaterals, 19 But the severity of 
the lesions remains the most important factor which is linked to the formation of 
collaterals,20 As angina is considered a symptom of myocardial ischemia and, since, 
without intervention, coronary atherosclerosis is almost uneqnivocally progressive 
in nature, a change in the process will have great clinical implications, It would thus 
appear that after 2 years of dietary intervention no longer exertional angina 
pectoris was present in 16 of the 39 patients and may point to an efficacious diet for 
angina pectoris, It is unlikely that other influences have played a major role in the 
outcome of the clinical course of the anginal symptoms, as anti-anginal drug-
medication was not altered drastically in any of the patients, Of far greater 
importance, as far as changes of symptoms is concerned, however, is the finding 
that there is a strong and significant correlation between persisting exertional 
angina and progression of coronary lesions, The fact that angina persisted in 17/21 
patients with progression, in 5/11 in those with stable lesions and only in 1/7 
patients whose coronary lesions showed regression, is of significance for the 
individual patient, Clearly, the patient with regression of coronary atherosclerosis 
has a better chance on an improved quality of life, 
Three and a half years after the intervention period 5/39 patients had died, In 
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order to put this figure into perspective, we have applied the findings of Storstein et 
al22 to our data. Storstein analyzed the national history of coronary artery disease, 
studied by coronary angiography in 795 consecutive patients with anginal com-
plaints and of a similar age group as that of the Leiden patients. Like most 
investigators, she found that prognosis was greatly determined by the extent of 
coronary artery involvement. The mean annual mortality rates of patients with 
one-, two- and three-vessel disease were 2.4, 4.9 and 62%, respectively. If we 
apply these data to the patients of the Leiden study with one- (n=7), two-
(n=ll) and three-vessel disease (n=21) and calculate mortality for the 3.5 years 
of follow-up, then 7 patients should have died in this period. In the Leiden study 
the mortality was of similar magnitude with five deaths. The fact that all five deaths 
occurred in the 21 patients with progression of disease underscores the clinical 
importance of the angiographic finding of even small changes in coronary diame-
ters. We infer from this that regression and arrest of progression did influence the 
clinical course of the patient. Slight changes in the growth rate of atheromatous 
plaques thus may have far reaching implications for survival. 
Blankenhorn et al.4,23 pointed out that an American and European men who 
died of myocardial infarction at the age of 40, the lesions have spread over 
coronary endothelial surface with a rate of 3 per cent per year. By the same token, 
men who died of myocardial infarction at 80 years of age had lesions that grew to 
cover 1 percent more of the endothelial coronary surface each year. The implica-
tion is that a small reduction in the growth rate of coronary lesions may produce a 
major delay in death from coronary disease. The arrest of progression of disease in 
18/39 patients (including 7/39 with regression) of the Leiden Trial may thus have 
important implications. It shows that diet may modify the course ofthe process that 
at the present time is the most important cause of death in the adult population of 
the industrialized world. This can only be proven, however, if further investigations 
are facilitated by non-invasive technology to study the course of atherosclerosis 
also in its early stages. We then may be able not to understand better the 
pathogenesis of progression but also the process of regression. 
Regression does not necessarily follow the exact pathway of progression in the 
opposite direction. Of interest is the finding of Vartiainen at al. 24 that during the 
war 1940-1945 the elevated atheromatous aortic plaques had diminished by 20-40% 
post-mortum, when compared to the 1933-1938 findings, but the incidence of fatty 
streaks had not decreased. Vartiainen's observation is in keeping with Str0m and 
Jensen's data25 which show that in 1941, soon after the beginning of World War II, 
the death rate from coronary heart disease decreased abruptly and considerably in 
Norway, a finding which seems to point towards regression, particularly of advanc-
ed plaques. Similar results were obtained in the Leiden Intervention Trial. The 2 
years application of the cholesterol lowering diet had significantly more effect on 
the severe(% D-stenosis >50%) lesions than on the lesser ones (<50% ).9 In the 41 
severe obstructions the mean change of diameters of the obstructions was -3.47%. 
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signifying that on average regression had occurred in all the severe lesions 
of the 39 participants. Of the 124 less severe lesions the mean change of diameter 
was +4.29%, thus showing progression of disease (p=0.02). It should be 
pointed out that each patient had at least one severe and one or more less severe 
lesions. This rules out the possibility that the mean regression of the more severe 
lesions and the mean progression of the lesser ones could be ascribed to individual 
characteristics, such as better adherence to diet. 
On the basis of the post-mortum observations of Vartianen et a! on aortic 
lesions, the epidemiologic data of Str0m and Jensen and the angiographic findings 
of the Leiden Trial, we conclude that their is evidence that with dietary interven-
tion atherosclerotic lesions in an advanced stage are more likely to regress than 
early ones. This statement undoubtedly needs confirmation, but it raises hope for 
the prevention of clinical sequelae of coronary artery disease not only in patients 
with early lesions, but even more so in those that have advanced atherosclerotic 
plaques. 
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APPENDIX PAPER I 
Cardiovasculaire risicofactoren bij mannen ( 49 jaar 
of jonger), een jaar na het eerste myocardinfarct 
J.D. Barth, G.T. Meester en J. Lubsen 
Samenvatting 
Cardiovasculaire risicofactoren (hypertensie, totaal-cholesterol, HDL-cholesterol, 
triglyceridengehalte in het serum, een positieve familie-anamnese voor hart- en 
vaatziekten, roken en (type 'A'-gedrag) werden onderzocht bij mannen (49 jaar of 
jonger), een jaar nadat deze een eerste myocardinfarct hadden doorgemaakt. In 
drie leeftijdsgroepen, respectievelijk 40 jaar of jonger, tussen 40 en 50 jaar, en 50 
jaar en ouder werd dit onderzoek verricht na beoordeling van de totale groep 
patienten die op de afdeling Hartbewaking gedurende een jaar (juni 1981-juni 
1982) met een myocardinfarct waren opgenomen. 
De resultaten lieten een verhoogd aantal risicofactoren in vooral de jongere 
groepen zien. Op grond daarvan moet overwogen worden of het niet aan te 
bevelen is, mede omdat met name vetstofwisselingsstoornissen bij de jongere 
groepen vaak voorkomen, een actief beleid te gaan voeren ter beinvloeding van 
deze risicofactor. Daamaast lijkt een mitigeren van andere aanwezige risicofacto-
ren, gezien het mogelijke gunstige effect op langere termijn, aanbevelenswaardig. 
Inleiding 
Volgens de huidige inzichten is het hartinfarct een multifactorieel bepaald ziekte-
beeld, waarvan gedurende een langere periode de cardiovasculaire risicofactoren 
mede de voortgang of de progressie bepalen. Gesuperponeerd op het basale 
atherosclerotische proces kan peracuut een afsluiting van een reeds vernauwde 
kransslagader ontstaan, bijvoorbeeld door een thrombus of een spasme. Het 
resultaat is dan het hartinfarct. 
Er zijn vele cardiovasculaire risicofactoren die de progressie van het atheroscle-
rotische proces bepalen, zoals geslacht, vetstofwisselingsstoornissen, hypertensie, 
roken, diabetes mellitus, positieve familieanamnese en een bepaald psychologische 
gedragspatroon (het zogenaamde type 'A'-gedrag).'·' 
Modificatie van risicofactoren heeft in grotere onderzoekingen tot op heden niet 
altijd tot een duidelijke verlaging van het risico geleid.4 Patienten met ziekte van de 
kransslagaderen hebben over het algemeen vee! risicofactoren. Uit het Lipid 
Research Clinics-onderzoek is naar voren gekomen dat verlaging van het choleste-
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rolgehalte de cardiovasculaire morbiditeit en sterfte kan verminderen. De implica-
ties daarvan voor de patient met een kransvataandoening verdienen heroverwe· 
~ncr 5,6 
;;::. e· 
Patienten die hun eerste myocardinfarct overleven, vormen een groep met een 
verhoogde kans op een recidief infarct. Wij hebben dergelijke patienten ruim 1 
jaar na hun eerste myocardinfarct opnieuw poliklinisch onderzocht en daarbij hun 
cardiovasculaire risicofactorprofiel samengesteld. 
Patienten en methoden 
Van de in totaal 1121 patienten die in de periode van 1 juni 1981 tot en met 1 juni 
1982 op de Coronary Care Unit van het Thoraxcentrum te Rotterdam waren 
opgenomen, bleken 252 mannen en 70 vrouwen een myocardinfarct te hebben 
doorgemaakt. De gemiddelde leeftijd van de mannen was 58,2 jaar, van de 
vrouwen 61,9 jaar. In het ziekenhuis overleden 36 mannelijke patienten en 16 
vrouwelijke patienten, zodat voor nader onderzoek in principe 216 mannen en 54 
vrouwen beschikbaar waren. Van deze 216 mannen waren er 52 ten tijde van hun 
eerste myocardinfarct 49 jaar of jonger. Ruim een jaar na het myocardinfarct 
bleken inmiddels 5 patienten te zijn overleden; daamaast hadden 2 een recidief 
myocardinfarct doorgemaakt, 2 een aortacoronaire bypass-operatie ondergaan en 
1 patient was geemigreerd. Uiteindelijk kwarnen 42 patienten onder de 50 jaar 
voor ons onderzoek in aanmerking. Van hen verschenen 30 op de polikliniek van 
het Thoraxcentrum. De overige 12 waren ten tijde van he! na-onderzoek allen nog 
in leven, maar niet gemotiveerd eraan deel te nemen. Van deze 30 patienten 
hadden 12 de leeftijd van 40 jaar of jonger, 18 de leeftijd tussen 41 en 49 jaar. Als 
controle werd een aselecte steekproef van 20 patienten genomen uit de patienten 
boven de 50 jaar. 
Tijdens het polikliniekbezoek werd een algeheellichamelijk onderzoek verricht 
en een cardiovasculaire vragenlijst afgenomen, gericht op. risicofactoren. Tevens 
werd totaal-cholesterolgehalte,7 HDL-cholesterolgehalte,8·9 en het triglyceridenge-
halte10 in het serum bepaald. Bij geen van deze patienten was een familiaire 
hyperlipoproteinemie en (of) diabetes mellitus v66r het hartinfarct bekend. 
De vragenlijst die aan de patienten werd voorgelegd, bevatte verder de volgende 
vragen: 
1. Rookt u op het ogenblik meer dan 5 sigaretten per dag en hoeveel rookte u 
voor het infarct? 
2. Heeft u hoge bloeddruk en (of) wordt u hiervoor behandeld (bloeddrukgrens-
waarde 150/90 mmHg)? 
3. Komen hart- en vaatziekten frequent in uw familie voor? (Kamen er in uw 
directe farnilie !eden voor die op 60-jarige leeftijd of nog jonger aan een hart- en 
vaatziekte zijn overleden of er aan lijden?). 
4. Heeft u het idee datu op het ogenblik onderhevig bent aan hevige emotionele 
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spanningen, die duidelijk gerelateerd zijn aan het door u doorgemaakte myocard-
infarct ( onbegrepen woede, rusteloosheid, een gevoel van een chronisch tekort aan 
tijd, snelle irritatie)? 
Resultaten 
Zoals uit tabel I valt op te maken, is er een duidelijk verschil in frequentie en ernst 
van vetmetabolismestooruissen tussen de jongere groepen en de groep die 50 jaar 
of ouder is. In de jongere groep is het cholesterolgehalte duidelijk hoger terwijl het 
HDL-cholesterolgehalte lager is dan bij de ouderen. 
Uit tabel II blijkt dat alle patienten uit de jongste groep v66r het hartinfarct 
sigaretten rookten en dat de frequentie na het infarct weliswaar lager was, maar 
uiet geheel tot nul was gedaald. In de oudere groepen nam het aantal rokers sterk 
af. Hypertensie kwam in de 3 groepen even vaak voor. Een positieve familie-
anamnese voor hart- en vaatziekten kwam vooral in de jongste groep voor, ook het 
zogenaamde type 'A'-gedrag kwam in de jongere groepen vaker voor dan in de 
oudere groep. 
In de figuur is het totale aantal cardiovasculaire risicofactoren per groep weerge-
geven. Het hoogste aantal risicofactoren is in de jongste groep te zien. 
TABEL I 
Scrumlipidegehalte in de verschillende leeftijdsgroepen van mannelijke patiCnten, een jaar na bet 
eerste hartinfarct 
Gehalten in mmoVl 
(gem. en uiterste 
waarden) 
Totaal-cholesterol 
HDL~cholesterol 
Triglyceriden 
•• p < 0.01 (t-toets) 
Bescbouwing 
Leeftijdsgroep in jaren 
~ 40 jr. 
(n = 12) 
9,30"'* 
(6,50- 16.20) 
0.91 
(0.79- 1.19) 
3,81 
(0.78- 8,73) 
41 - 49 jr. 
(n = 18) 
7.20** 
(5,90- 8,51) 
1.02 
(0.71- 1.29) 
2.87 
(1.49 - 6,86) 
~50 jr. 
(n = 20) 
7.11 
( 4,52 - 7 ,83) 
1.09 
(0.89 - 1,38) 
2,69 
(1.62 - 4,68) 
Hoewel de 3 groepen van patienten relatief klein zijn zodat conclusies slechts met 
terughoudendheid geformuleerd kunnen worden, lijkt het toch frappant dat er 
ruim een jaar na het doormaken van het eerste myocardinfarct nog steeds een 
groot aantal risicofactoren bij jonge mensen aanwezig blijft. Het hoge tot ver-
hoogde cholesterolgehalte in de jongste groep is des te emstiger gezien het feit dat 
dit vrij zeker met de leeftijd verder zal gaan stijgenY In onze patientengroep had 
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de jongste gtoep de hoogste cholesterolwaarden. Het HDL-cholesterolgehalte, 
door velen als 'anti-atherogeen' beschouwd aangezien het negatief geassocieerd is 
met het v66rkomen van hart- en vaatziekten,'2 was niet significant verschillend in 
de 3 gtoepen, wei was er een tendens tot lagere waarden in de jongere gtoep. Of de 
triglyceridenspiegels een aparte risicofactor voor hart- en vaatziekten zijn, is nog 
niet duidelijk. Wei is er in dit onderzoek sprake van een trend tot een hogere 
waarde in de jongere leeftijdsgtoep. 
TABEL II 
Risicofactoren in verschillende leeftijdsgroepen van mannelijke patienten, een jaar na bet eerste 
hartinfarct 
Risicofactoren 
Bloeddruk > 150190 (mmHg) 
Hypertensie in voorgeschiedenis 
Sigaretten rokcn v66r 
Sigaretten roken na 
Aantal sigaretten v66r (SD) 
per dag gem. na (SD) 
Positieve familie-anamnese 
Type ·A ·-gedrag 
FIGURE 1 
Leeftijdsgroep in jaren 
~ 40 41-49 
(n ~ 12) (n ~ 18) 
4 4 
6 5 
12 15 
3 9 
24 (10) 17 (12) 
4 ( 6) 5 ( 6) 
10 9 
8 13 
Aantal risicofactoren per leeftijdsgroep (gemiddelde en standaard deviatie) 
aantal risicofactoren 
per patient 6 
5 
4 
3 
2 
leeftijdsgroep in jaren 
~ 40 41-49 
p < ro-s 
Kruskal en 
Wallists 
~ 50 
;::-:50 
(n ~ 20) 
4 
5 
12 
4 
18 (15) 
3 ( 4) 
2 
4 
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Belangrijk lijkt verder de constatering dat aile patienten uit de jongste leeftijds-
groep sigaretten hadden gerookt voor het hartinfarct en dat een groot aantal ook 
nog na het infarct hypertensie had. Dit terwijl het hartinfarct waarschijnlijk door 
een dating van de linker-ventrikelfunctie zelf reeds een bloeddrukverlagend effect 
heeft. Ook een positieve familie-anamnese voor een cardiovasculaire aandoening 
en een type 'A'-gedrag kwamen in de jonge groep vaker voor. 
In verscheidene onderzoekingen in verschillende Ianden is bet voorkomen van 
risicofactoren bij jonge hartpatienten nagegaan. Dolder et al. in the Nine Coun-
tries Study vonden een verhoogd totaal-cholesterolgehalte (7,25 mmolll of boger) 
bij jonge mannen na een eerste infarct, vooral in geindustrialiseerde Ianden. Het 
percentage varieerde echter aanmerkelijk; zo bedroeg het percentage patienten 
met verhoogd totaal-cholesterolgehalte in Israel45%, in India slechts 1%. Hyper-
tensie als risicofactor bestond bij 23% van de patienten in Australie en bij 7% in 
Singapore. Roken varieerde van 86% in Singapore tot 96% in de Verenigde 
StatenY Roskamm et al. bestudeerden bij mannen onder de 40 jaar ook de 
frequentie van cardiovasculaire risicofactoren. Zij vonden een verhoogd choleste-
rolgehalte (8,0 mmol/1 of boger) bij 73% van hun patienten, terwijl 93% voor bet 
myocardinfarct sigaretten rookte en 30% hypertensie had. 14 V anhaelke et al. 
hadden gelijksoortige bevindingen bij een Belgische patientengroep." Glover et 
al. vonden in de leeftijdsgroep van 36 jaar en jonger in de Verenigde Staten dat 
98% van de patienten die een hartinfarct hadden doorgemaakt, sigaretten had 
gerookt voor bet infarct en dat 21% hypertensie had gehad. Bij 20% kwam 
hyperlipidemie in de anamnese voor. 16 Goldstein et al. tenslotte vonden voor 
hyperlipoproteinemie bij gezonde mannen onder de 40 jaar een percentage van 
60. 17 
Gezien bet risicoprofiel van onze postmyocardinfarctpatienten, mede gezien de 
recente resultaten van de Lipid Research Clinics,5•6 Jijkt een actiever beleid, gericht 
op secundaire preventie, op zijn plaats. Hierbij moet worden aangetekend dat van 
be1nvloeding van de hypercholesterolemie op dit moment geen eenduidig effect 
bekend is. Mede hierom lijkt helaas de twijfel zoals die o.a. door Oliver is 
uitgesproken over het nut van risicofactormodificatie, gerechtvaardigd. 18 Hiertege-
nover staat dat er sinds het Coronary Drug Project, waarbij slechts met clofibraat 
en nicotinezuur gewerkt is/9 meer inzicht in het vetmetabolisme is gekomen en dat 
men nu meer keuze heeft om bet juiste medicament bij een specifieke aandoening 
te gebruiken. 
Ten slotte moet gesteld worden dat, gezien bet verschillend voorkomen van 
cardiovasculaire risicofactoren in de verschillende leeftijdspgroepen, er ook sprake 
kan zijn van een andere wijze van ontstaan bij jongere en oudere hartinfarctpa-
tienten. 
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Conclusie 
In de jongste groep (onder de 41 jaar) mannelijke patienten die een hartinfarct 
hadden overleefd en ruim een jaar na dit doorgemaakte hartinfarct opnieuw 
werden onderzocht, bleek dat alle patienten voor het hartinfarct hadden gerookt. 
Zij hadden ook een significant hoger totaal-cholesterolgehalte in het serum dan de 
oudere leeftijdsgroepen. Een positieve familie-anamnese voor een cardiovascu-
laire aandoening hadden 10 van de 12, terwijl van 6 patienten bekend was dat ze 
hypertensie hadden. Tevens kwam het zogenaamde type 'A'-gedrag meer bij hen 
voor (8 van de 12). 
Gesteld kan worden dat bij patienten die 49 jaar of jonger zijn ten tijde van hun 
eerste myocardinfarct meer risicofactoren voorkomen dan bij oudere patienten. 
Hoewel bij deze patienten na het doormaken van het hartinfarct actief getracht is 
de risicofactoren te mitigeren~ bleken deze een jaar later echter nog weinig 
veranderd te zijn. Vooral misschien bij relatief jonge patienten, zeker in geval van 
hoge tot verhoogde totaal-cholesterolgehalten, moet overwogen worden deze 
medicamenteus te be1nvloeden, als dieetmaatregelen onvoldoende resultaat 
hebben. 
Summary 
Cardiovascular risk factors in men (49 years or younger), one year after their first 
myocardial infarction. - Cardiovascular risk factors (hypertension, total serum 
cholesterol, HDL-cholesterol, serum triglycerides, a positive family history of 
cardiovascular disease, smoking and type 'A' = coronary prone behavior) were 
studied in men (49 years or younger), one year after they had had their first 
myocardial infarction. In three age groups, 40 years or younger, 41-49 years and 50 
years and older, respectively, this investigation was carried out after assessment of 
the total group of patients who had been admitted with a myocardial infarction to 
the coronary care unit in a period of one year (June 1981- June 1982). 
The findings revealed an increased number of risk factors especially in the 
younger groups. For this reason, the question should be considered, partly in view 
of the fact that abnormalities of the lipid metabolism are frequent, especially in the 
younger age groups, whether it would not be advisable to start an active campaign 
to influence this risk factor. Mitigation of the other risk factors present is also to be 
recommended, because of the possible favourable longterm effect. 
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Summary 
Progression and regression of coronary 
atherosclerosis. 
Thesis Jacques D. Barth, Rotterdam, 1986. 
Manifestations of coronary heart disease like angina, pectoris acute myocardial 
infarction and sudden death are rapid sudden processes of a slower, generally 
progressive underlying coronary atherosclerotic disease. Important factors that 
may influence atherosclerosis are the plasma lipoproteins. According to their 
density, which is determined by the lipid-protein ratio, the lipoproteins can be 
divided into 4 subclasses: chylomicrons, very-low-density-lipoproteins (VLDL), 
low-density-lipoproteins (LDL) and high-density-lipoproteins (HDL). The level of 
the LDL fraction is strongly positively correlated to a progressive course of 
atherosclerosis and HDL on the other hand is inversely correlated to the natural 
(progressive) course of atherosclerosis. The higher the blood LDL fraction level, 
the more rapid the progression of coronary artery disease; the higher the blood 
HDL fraction level, the slower the progression of the disease. This thesis describes 
several investigations in patients with severe coronary atherosclerosis. The inci-
dence of a disordered lipid metabolism is evaluated. The biochemical data in the 
process of atherosclerosis are assessed and the results of a lipid lowering diet 
intervention study on progression of coronary atherosclerosis and its complications 
are discussed. Although the complications of coronary artery disease, as mentioned 
above, are clinicaly important phenomena, the underlying disease remains the most 
important factor in the etiology of these manifestations. Our investigation into risk 
factors one year after a first acute myocardial infarction in all patients who had 
been admitted to the coronary case unit during the period of one year undertaken 
proving the point that the younger the patient, the more lipid risk factors were 
present (a significantly higher 'atherogenic' total-cholesterol and a lower 'anti-
atherogenic' HDL-cholesterol). The total sum of risk factors was also the highest in 
the youngest age group (Chapter II). 
As postheparin lipoprotein lipase activities, hepatic lipase (HL )* and lipopro-
tein lipase (LPL), are important modulators of the lipoprotein metabolism, notably 
of the ratio LDL- to HDL-cholesterol, two matched groups of patients with and 
without angiographic evidence of coronary atherosclerosis have been studied with 
respect to the possible lipid risk factors, the postheparin lipoprotein lipases and 
hormones suspected of being atherosclerosis related. When a group of normolipe-
mic patients who had undergone coronary angiography without apparent atheros-
clerosis was compared biochemically with a matched group of patients who showed 
* Synonym of liver lipase activity (LLA). 
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angiographically severe and diffuse coronary atherosclerosis, the most striking 
difference between the groups was the significant different activity of one of the 
postheparin lipoprotein lipases. HL was significantly lowered in the diffuse and 
severe atherosclerotic group of patients, while normal values were observed in 
atherosclerosis-'free' subjects. No significant difference could be observed for the 
LPL-values (Chapter III). 
As several hormones may influence lipid transport and atherosclerosis, the 
following hormones were measured and compared in both groups of patients: 
glucagon and the estradiol - 17P - testosterone ratio were significantly higher in 
patients with diffuse severe atherosclerosis while thyroid hormone, insulin, prolac-
tin, human growth hormone and cortisol values were not essentially different 
between the two groups of patients (Chapter III). 
As specific lipoprotein fractions are important endogeneous factors that deter-
mine to a certain extent the rate of progression of coronary atherosclerosis, diet 
seems to be one of the most important exogeneous regulating factors, especially a 
diet low in cholesterol content and enriched in polyunsaturated fatty acids. Other 
studies have shown that in all species investigated including the human species, an 
elevation of the intake of atherogenic food constituents enriched in saturated 
cholesterol resulted in a more rapid development of atherosclerosis in comparison 
with groups of animals and men in which this dietary measure was not taken. As 
lipid metabolism of men differs from that in animal study models, a trial with the 
aim to decelerate the natural progressive course of coronary atherosclerosis and its 
acute superimposed manifestations in men is a great challenge to meet. In an effort 
to try to answer the underlying basic question 'Can a lipid lowering diet decelerate 
progression or even induce regression of coronary atherosclerosis?', a secundary 
diet intervention program was started, called the Leiden Intervention Trial. To 
study the natural course of coronary atherosclerosis sequentional angiographies 
were performed. 
However, investigations of the natural course of coronary atherosclerosis by 
sequential angiograms by visual assessment are not reliable enough to suit the aim 
of the study, due to the large inter- and intra-observator variations in interpreta-
tion. Therefore, a computerized quantitative method that allows the measurement 
of absolute and relative arterial dimensions from coronary cineangiograms was 
used for the above mentioned trial. By this method two identical coronary 
segments of the same patient on two arteriograms with a two-year interval can be 
compared with sufficient accuracy and precision. A scoring coronary system has 
been developed for comparison of the arterial dimensions pre- and post-interven-
tion; a flow dependent weighting factor corrects for the different sizes of the 
arterial segments. (Chapter V). 
In the 39 participating patients, who had undergone 2 sequential coronary 
angiograms, an assessment was made as to the effect of the prescribed diet on lipid 
fractions and atherosclerotic lesion growth (Chapter IV). In 21 patients progres-
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sion of the disease occurred while in 18 a stabilization or even regression of 
coronary atherosclerosis was observed. A positive and significant correlation was 
found between the total-cholestero!JHDL-cholesterol ratio and coronary atheros-
clerotic lesion growth (Chapter HI). The patients, who eventually benefitted the 
most from the dietary intervention, were those patients who showed an initial high 
total-cholesteroi/HDL-cholesterol ratio and orginally had a high dietary intake of 
saturated fatty acids (Chapter IV). 
As has been mentioned before, several enzymes and hormones are directly or 
indirectly involved in the natural progressive course of coronary atherosclerosis. 
Several atherogenesis linked hormones were studied and no difference could be 
established between the progression and the no lesion growth or regression group 
for insulin, testosterone, estradiol and cortisol. A significantly higher triiodothyro-
nine (T 3) value was found in those patients that showed no lesion growth or even 
regression of coronary atherosclerosis (Chapter IV). Lipoprotein lipase activities 
as important lipid modulators were assessed and correlated to coronary atheroscle-
rotic lesion growth. In a linear regression analysis a significant positive correlation 
was established between hepatic lipase and the coronary score. This implies that 
the lower the hepatic lipase value, the more progressive the nature of the disease. 
By multivariate analysis, hepatic lipase was shown to be the variable correlated 
most strongly with regression of coronary atherosclerosis. 
However, T3 and HDL are also important and independent factors that add to 
the probability to induce regression of coronary atherosclerosis (Chapter VI). 
To conclude, the clinical significance of the changes in vascular lumen diameter 
can be made by assessing three clinical aspects: 
1. The presence of angina pectoris at termination of the trial. 
2. Survival of patients after termination of the study. 
3. The electrocardiogram at the beginning and at termination of the trial. 
The analysis of angina pectoris showed that the severity of complaints had 
diminished in the total patient population. At termination of the trial, a signifi-
cantly positive correlation was found between regression of atherosclerosis and the 
disappearance of anginal complaints. 
Concerning the survival three and a half year after termination of the study, a 
total of 5 (out of 39) patients had died, all belonging to those that showed lesion 
growth. 
The electrocardiogram is considered an indirect method for assessing myocardial 
perfusion. The following results were observed: both the initial ECG and the ECG 
that was performed at termination showed a positive correlation to the severity of 
coronary atherosclerosis (Chapter VII). We infer from these findings that even 
minor changes in coronary atherosclerotic stenoses may have important clinical 
implications for individual patients. Of special interest seems to be the observation 
that especially the most severe stenoses are the ones most liable to benefit from the 
intervention. 
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Derived from the above mentioned data we propose as hypothesis that a 
different mechanism exists for regression and progression of coronary atheroscle-
rosis. An acceleration of the reversed cholesterol transport by HDL-C and an 
increased excretion of cholesterol into bile by HL may explain the phenomena of 
regression of atherosclerosis. T3 as an indicator of the metabolic activity could 
place this process on a higher turnover level. 
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Progressie en regressie van coronaire 
atherosclerose. 
De rol van het dieet, de lipoprote'inen en de lipases. 
Dissertatie Jacques D. Barth, Rotterdam, 1986. 
Sam en vatting 
Complicaties van coronaire atherosclerose zoals het acute myocardinfarct, de 
plotse dood of angina pectoris zijn mogelijk snelle veranderingen die optreden in 
of op de vaatwand bij een chronisch langzaam progressief atherosclerotisch proces. 
Vele factoren be1nvloeden dit langzame onderliggende lijden. Een belangrijke 
factor hierbij is een gestoord vetmetabolisme. Verscheidene fracties zijn a! naar 
gelang hun samenstelling, (vet en eiwitverhouding) en gewicht te onderscheiden. 
In totaal worden vier hoofdklassen van deze fracties of lipoprote!nen onderschei-
den. Zo zijn er met toenemend gewicht en afname van grootte de volgende 
fracties: de chylomicronen, de very-low-density-lipoproteins (VLDL), de low-
density-lipoproteins (LDL) en de high-density-lipoproteins (HDL). Aangezien de 
LDL-fractie sterk positief gecorreleerd is met de frequentie. van cardiovasculaire 
aandoeningen, wordt deze fractie als atherogeen beschouwd, terwijl de HDL-
fractie, die juist negatief met deze aandoeningen is gecorreleerd, als anti-athero-
geen wordt gezien. Vastgesteld is dat hoe hoger het LDL-gehalte is enlof hoe lager 
het HDL-gehalte, hoe sneller de progressie van coronaire atherosclerose is. Deze 
dissertatie betreft onderzoekingen bij patienten met emstige coronaire atheroscle-
rose; naar de ernst van de vetstofwisselingsstoornissen, de biochemische parame-
ters bij het proces van atherosclerose en vooral of met een cholesterol verlagend 
dieet een verdere voortgang van de coronaire atherosclerose en de complicaties 
hiervan tot staan konden worden gebracht. Uiteraard zijn de complicaties van het 
coronair vaatlijden uiterst belangrijk echter, het onderliggende proces blijft dat-
gene dat beinvloed moet worden (Hoofdstuk I). 
Om allereerst tot inventarisatie te komen van het voorkomen van vetstofwisse-
lingsstoornissen en andere risicofactoren voor cardiovasculaire aandoeningen, 
werden aile mannelijke patienten, die op de hartbewaking gedurende een jaar 
opgenomen waren geweest, beschouwd een jaar nadat ze een eerste hartinfarct 
hadden doorgemaakt. Er werd met name naar leeftijd gekeken, want een lange 
termijn interventie, indien noodzakelijk, lijkt vooral bij jongere patienten op zijn 
plaats. De conclusies van deze studie zijn emstig te noemen in die zin dat juist de 
jongste leeftijdsgroep de meeste risicofactoren heeft en dat met name het athero-
gene totaal-cholesterol verhoogd en het anti-atherogene HDL-cholesterol verlaagd 
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waren, ook in vergelijking met voor de bijpassende leeftijdsgroep behorende 
normaalwaarden (Hoofdstuk II). 
Een volgende stap om te komen tot inventarisatie van modulatoren bij coronaire 
atherosclerose was ons onderzoek waarbij twee groepen mannelijk patienten 
werden vergeleken aan de hand van bet wei of niet aanwezig zijn van diffuse 
ernstige coronaire atherosclerose, zeals aangetoond bij coronair-angiografie. Bij 
deze studie werd met name gekeken naar het en do thee! gelocaliseerde lipoproteine 
lipase en het leverlipase die bij het LDL en het HDL metabolisme een belangrijke 
rol spelen. Tevens werden in beide groepen verscheidene hormonen bepaald die 
aan atherosclerose gerelateerd zijn (Hoofdstuk III). Geconcludeerd werd dat bet 
lever lipase of hepatische lipase duidelijk significant verlaagd is bij mannen met 
uitgebreide en diffuse coronaire atherosclerose. De activiteit van lipoproteine 
lipase was niet verschillend in beide groepen. De glucagon-spiegel en de estradiol-
17~ - testosteron-verhouding waren significant hoger in de atherosclerotische 
groep. Schildklierhormoon, insuline, prolactine, groeihormoon en cortisol waren 
niet wezenlijk verschillend in beide groepen. 
Zoals reeds eerder gesteld werd, zijn sommige lipiden-fracties met atheroscle-
rose gecorreleerd. Daar cholesterol zowel endogeen wordt geproduceerd als 
exogeen via bet voedsel word! opgenomen, lijkt bet zinvol om tot vermindering 
van vetrijke maaltijden, met name van verzadigde vetzuren, te komen, aangezien 
deze als atherogeen beschouwd worden. Een vegetarisch dieet met een hoge 
verhouding van meervoudig-onverzadigde tot verzadigde vetzuren bij een geringe 
hoeveelheid cholesterol, zou mogelijk tot teruggang van atherosclerose kunnen 
leiden. Een probleem dat bij een dergelijk onderzoek naar voren komt, heeft te 
maken met het natuurlijke beloop van coronaire atherosclerose. Dit is een 
langzaam progressief proces waarbij het vele jaren duurt voordat hierop gesuper-
poneerde complicaties optreden. Om de cruciale vraag 'Kan door middel van een 
cholesterol-verlagend dieet een vermindering van de voortgang of zelfs teruggang 
van coronaire atherosclerose bereikt worden?' te kunnen beantwoorden, werd een 
secundaire interventie studie met dieet aileen geentameerd: de Leidse Interventie 
Trial. Voordat deze vraag beantwoord kon worden, moesten de volgende proble-
men betreffende o.a. de betrouwbaarheid van de methode die in de studie gebruikt 
werd, opgelost worden. 
Een in de laatste jaren ontwikkelde methode om het groeiproces van atheroscle-
rose in de patient te volgen is bet bij herhaling verrichten van coronair-angiografie. 
Hoewel een coronair-angiografie met behulp van een contrast middel slechts dat 
aanduidt wat zich in het lumen bevindt, kan men met deze methode toch bet 
natuurlijke beloop (de progressie) van het proces van atherosclerose observeren. 
Een volgend probleem dat naar voren kwam is het feit dat indien men met relatief 
korte tussenliggende perioden coronairangiografieen herhaalt, de mate van nauw-
keurigheid van bet volgen van veranderingen afneemt. Visuele interpretatie aileen 
is, gezien de grote verschillen bij herhaalde interpretatie van dezelfde angiografie 
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door dezelfde waamemer en bij herhaalde interpretatie door verscheidene waarne-
mers, voor een onderzoek met herhaalde angiografieen ongeschikt. Een kwantita-
tieve methode ter analyse van de diameters van de coronaire vaten is daarom 
vereist. Voor deze studie was een gecomputeriseerde kwantitatieve analyse 
beschikbaar gekomen waarvan de nauwkeurigheid van het systeem grater is dan de 
normale biologische variatie, zodat dit systeem geschikt geacht werd om gebruikt 
te worden bij deze interventiestudie, waarbij d.m.v. sequentiele coronair-angiogra-
fieen de veranderingen van de diameter van het lumen onder behandeling met een 
vegetarisch dieet waargenomen werden. Hiervoor werd rekening houdend met de 
mate van bloedstroming door een betreffend vasculair lumen een waarderingssys-
teem ontwikkeld (Hoofdstuk V). 
Van 39 patienten, waarbij uiteindelijk twee angiografieen waren gemaakt, werd 
de invloed van het dieet op met name het vetmetabolisme en de coronaire 
atherosclerose onderzocht (Hoofdstuk IV). Bij 21 patienten vond verdere progres-
sie van hun lijden plaats, terwijl bij 18 patienten stabilisatie of zelfs teruggang van 
de ernst van coronaire atherosclerose bereikt werd. Alle patienten hadden op het 
eerste coronair-angiogram een ernstige lumenvernauwing. Een manier om tot een 
score te komen moest ontwikkeld worden waarbij rekening gehouden kon worden 
met 9 belangrijke coronaire segmenten. Bij deze waarderingsmaat werd er vanuit-
gegaan dat bepaalde segmenten. waar meer bloed doorheen moet kunnen stromen 
(aangezien een grote spiermassa voorzien moet worden) belangrijker waren dan 
andere (Hoofdstuk V). Op grond van deze twee jaten durende studie werd 
vastgesteld dat behandeling met dieet aileen regressie of stabilisatie van de 
coronaire atherosclerose kan bewerkstelligen. Er was een duidelijke positieve 
correlatie tussen de totaal-cholesterol - HDL-cholesterol - verhouding enerzijds 
en de gemiddelde verandering van de absolute coronairscore anderzijds (Hoofd-
stuk V). Bij nadere analyse bleek dat die patienten die het meeste baat bij dit dieet 
hadden, de groep patienten was, die aanvankelijk een hoge serum totaal-choleste-
rol/HDL-cholesterol-verhouding had en relatief vee! verzadigd vet hadden genut-
tigd (Hoofdstuk IV). 
Zoals eerder werd gemeld, zijn verscheidene enzymen en hormonen direct of 
indirect van belang bij de progn::ssie van coronaire atherosclerose. T.a.v. de 
hormonen die onderzocht werden op hun eventuele relatie tot progressie van 
coronaire atherosclerose werd er geen verschil gevonden tussen de groepen met 
respectievelijk zonder progressie wat betreft insuline, testosteron, oestradiol en 
cortisol. Wei werd een significant hoger triiodothyronine (T3) gevonden in de 
groep zonder progressie (Hoofdstuk V en VI). Voorts zijn in het interventieonder-
zoek als modulatoren van het lipiden metabolisme, de postheparine lipoproteine 
lipasen en hun relatie met het a! of niet optreden van coronaire diameterverande-
ringen betrokken. Hierbij werd vastgesteld dat er een significant lineair positief 
verband aanwezig was tussen de leverlipase activiteit en de toename van de 
coronaire 'score', d.w.z. de regressie van het atherosclerotische proces. De groep 
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zonder progressie had significant hogere leverlipase waarden en bij 'multivariate' 
analyse kwam het leverlipase naar voren als de variabele die het sterkst gecorre-
leerd was met het optreden van regressie van coronaire atherosclerose. Daamaast 
spelen T3 en HDL-C oak een belangrijke rol (Hoofdstuk VI). 
Tot slot werd de klinische betekenis van deze veranderingen in de diameter van 
de coronair arterien onderzocht. Er werden drie klinische parameters beschouwd. 
1. De aanwezigheid van angina pectoris aan het einde van de studie. 
2. Het al dan niet in Ieven zijn van de participanten geruime tijd na beeindiging 
van de stu die. 
3. Het ECG bij het begin en aan het einde van de studie. 
Uit de analyse van de gegevens bleek dat de ernst van de angina pectoris in de 
totale groep patienten aanmerkelijk verminderd was. Bij differentiatie naar de 
diameterverandering werd vastgesteld dat er aan het einde van de studie significant 
minder angina pectoris in de groep met regressie voorkwam dan bij de overige 
patienten. Drie en half jaar na beeindiging van het onderzoek waren 5 patienten 
overleden, allen behorend tot de groep met duidelijke progressie. Het ECG als 
indirecte maat voor de myocardiale perfusie vertoonde het volgende: zowel het 
initiele ECG als het ECG dat bij beeindiging van de studie werd gemaakt, kwamen 
redelijk goed overeen met de ernst van de coronaire atherosclerose, dit zowel bij 
het begin als aan het einde van het onderzoek (Hoofdstuk VII). Geconcludeerd 
werd dat voor de individuele patient zelfs een geringe verandering van de diameter 
van de coronaire arterien grote klinische implicaties heeft. Daarbij hebben veran-
deringen ter plaatse van de emstigste stenosen de grootste klinische consequenties. 
Onze hypothese is dat eventuele regressie van coronaire atherosclerose veroor-
zaakt wordt door versnelling van het 'reversed' cholesterol transportmechanisme 
onder invloed van het lever!ipase, waarbij meer cholesterol in de gal wordt 
uitgescheiden. Dit gehele proces kan wellicht verder gestimuleerd worden door 
een verhoging van het metabolisme weergegeven door een hoge T,-waarde. 
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